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In December 1988 the Head of the Radiation Protection Programme established an International 
Panel of Independent Experts in order to draft recommendations on the feasibility of carrying out 
studies on the health effects from  environmental exposure to ionizing radiation as  a consequence 
of the Chernobyl nuclear reactor accident that took place in April 1986.  This panel consisted of 
the following  individuals: 
Sir Richard Doll 
(Chairman) 
Dr.  J.D.  Boice 
Dr.  J.  Esteve 
Prof.  G.  Silini 
Dr. J.W.  Thiessen 
Imperial Cancer Research Fund 
Cancer Epidemiology and Clinical Trials Unit 
Oxford  University,  UK 
Chief of Radiation Epidemiology Branch 
National Cancer Institute 
Bethesda, MD,  USA 
Unit of Biostatistics Res.  and Information 
International Agency for  Research on Cancer 
Lyon,  France 
Secretary of UNSCEAR (retired) 
Lavere 
Bergamo, Italy 
Vice  Chairman 
Radiation Effects Research Foundation 
Hiroshima-Nagasaki, Japan 
The Panel met in Brussels on 27  and 28 February 1989.  A Task Group, also established by the 
Head of the Radiation Protection Programme prior to that meeting, had prepared a draft report 
entitled "Feasibility of Studies on Health Effects in Western Europe due to the Reactor Accident 
at Chernobyl".  This Task Group consisted of Prof. AM. Kellerer and Dr. J.  Breckow, University 
of Wiirzburg;  Prof.  E.G.  Knox,  University  of Birmingham;  and  Dr.  S.  Richardson,  INSERM, 
Villejuif.  At the February meeting the Panel met the Task Group to discuss  this  draft report, 
amend  it  where  necessary  and  draft  conclusions  and  recommendations  with  respect  to  the 
feasibility  of  health  effect  studies.  The  following  section  of  this  report  contains  the 
recommendations of the Panel, to which is  attached the final version of the Task Group report. 
Together they represent the consensus of both the Panel and  the Task Group. 
- Ill -The reactor accident at Chernobyl in 1986 caused widespread concern throughout the population 
of the European Community because of the potential radiological consequences.  The accident 
also  drew  attention  to  some  gaps  in  our  knowledge  of the  behaviour  and  health  hazards  of 
radioactive  contamination  in  the  environment  and  highlighted  the  need  to  improve  the 
preparedness to deal with a large-scale nuclear accident.  As a consequence, the Commission of 
the European Communities  proposed  a revision  of the Radiation Protection Programme  1985-
1989  (COM(87)332 Final) with  the specific  aim  of initiating additional radiological  research  to 
cover  the  lacunas  in  knowledge  revealed  by  the  Chemobyl  accident.  The  revision  of  the 
Radiation  Protection  Porgramme  was  approved  by  the  Council  on  21  December 1987  with  a 
budget of 10  Mio.ECU (O.J.  No.  L 16/44 of 21.1.88).  The revision  outlined 10 specific lines of 
research: 
1.  evaluation  of  the  reliability  and  meaningfulness  of long  distance  atmospheric 
transfer models; 
2.  evaluation of data on the transfer of radionuclides in  the food  chain; 
3.  feasibility of epidemiological studies on health effects in  the population; 
4.  radiological aspects of nuclear accident scenarios; 
5.  underlying data for derived emergency levels; 
6.  improvement  of practical  countermeasures  with  respect  to  the  agricultural  and 
aquatic environment; 
7.  improvement of practical countermeasures with respect to the urban environment; 
8.  improvement of practical countermeasures with  respect to preventive medication; 
9.  monitoring and surveillance in  accidental situations; 
10.  treatment methodologies of exposed persons. 
This report responds to the Post-Chernobyl research action number 3 in considering what health 
effects  might  be caused  by  the radioactive contamination of Member States by  the accident at 
Chernobyl  and  whether  the  increased  incidences  of any  anticipated  health  effects  would  be 
amenable to further study.  The feasibility study was undertaken by scientists from  three institutes 
with  an established reputation in  the fields  of radiation effects  and epidemiology,  namely, 
Prof. A.M.  Kellerer and Dr. J.  Breckow from  the Institut fiir  Medizinische Strahlenkunde of the 
University of Wiirzburg, F.R.G., Prof. E.G. Knox from  the Department of Social Medicine of the 
·IV· University of Birmingham, U.K. and Dr. S.  Richardson of the Institut National de la Sante et de 
la  Recherche  Medicale  in  Paris,  France.  The study  was  based  on  a  review  of the  radiation 
exposures  accumulated by  the public  in  different Member States as  a  result  of the radioactive 
contamination from  Chernobyl,  a consideration of the possible  health effects which  might  arise 
from  the radiation,  an estimation of the incidences  using  current risk  coefficients  for  different 
sections of the public,  and  a calculation of the probability that an epidemiological study  might 
reveal the radiation induced  health effects in  the background of normal human disease. 
The  feasibility  study  has  been  reviewed  by  an  international  panel  of distinguished  scientists, 
namely  Sir  Richard  Doll  (Chairman)  from  the  Imperial  Cancer  Research  Fund  Cancer 
Epidemiology  and  Clinical  Trials  Unit  of the  University  of Oxford,  U.K.,  Dr.  J.W.  Thiessen 
(Secretary),  Vice  Chairman  of the  Radiation  Effects  Research  Foundation  in  Hiroshima  and 
Nagasaki, Japan, Dr. J.D. Boice from  the Radiation Epidemiology Branch of the National Cancer 
Institute  in  Bethesda,  U.S.A,  Dr.  J.  Esteve  from  the  Unit  of  Biostatistics  Research  and 
Information of the International Agency  for  Research on Cancer in  Lyon,  France and  Prof.  G. 
Silini  (former Secretary of UNSCEAR) from  Lavere, Bergamo, Italy.  The recommendations of 
this panel of experts, which provide a concise summary of the feasibility study are presented first 
in  this  report. 
The feasibility study has  been purposely written for  the educated layman  and should  appeal to 
all  those interested in the potential health effects from  the reactor accident at Chernobyl, as well 
as  those scientists and medical experts who are professionally involved in research and regulation 
in  radiological protection. 
-v-RECOMMENDATIONS 
OF AN INTERNATIONAL PANEL OF INDEPENDENT EXPERTS 
on 
THE FEASIDILITY OF STUDIES ON HEALTH EFFECTS IN 
WESTERN EUROPE DUE TO THE REACTOR ACCIDENT 
AT  CHERNOBYL Introduction 
The Panel has considered whether studies of health effects potentially related to environmental 
releases from  the Chernobyl reactor accident would be useful.  In doing so,  it has evaluated the 
exposure patterns and the dose levels within the European Community, the different health effects 
that  might  be induced  by  such  doses,  and  the  likelihood  that  epidemiological  studies  could 
produce scientifically useful information.  In the following,  the Panel indicates the conclusions of 
these  evaluations  and  recommends  a  course  of action  that  it  considers  to  be  prudent  and 
scientifically reasonable. 
Exposures in  the European Community 
Doses to populations of member states due to the Chernobyl accident vary from 0.05 mGy to 0.9 
mGy in the first year after the accident, with a total exposure in all following years not exceeding 
that in  the first  year.  Averaged  over  the  population,  such  exposure  levels  are  less  than  the 
normal background  radiation levels  that result  in  annual doses  of the order of 1 m  Gy.  As  a 
consequence, epidemiologic (or, for that matter, any) health effect studies comparing populations 
of entire member states could not be expected to be productive and the Panel recommends that 
no consideration be given to them. 
Within  member  states,  and  especially  in  those  with  the  highest  depositions  of  radioactive 
substances from  the accident, smaller areas exist where the doses to the population considerably 
exceed  the average for  the  country as  a whole.  If any study is  to have  a chance of detecting 
any effect it will only be one in which comparisons are made between relatively small areas within 
member states that have experienced the biggest differences in exposure. 
Possible Health Studies 
The Task Group report discusses the health effects in humans that have been shown to be related 
to previous radiation exposure.  These health effects are: 
short-term effects in  the exposed, including developmental effects induced in  the foetus 
or embryo, occurring within a few weeks; 
long-term  effects,  ie  cancer  and  possibly  heritable  genetic  effects  that  become 
demonstrable years after exposure, or in  future generations. 
·IX· Most short-term effects require substantially elevated doses of radiation, ie of the order of grays, 
and  are therefore  not  expected  in  the  siutation  discussed  here.  Some developmental  effects, 
expressed  as  congenital malformations, could conceivably be induced by  doses  less  than 1 gray, 
but the low probability of such effects being induced, given the post-Chernobyl exposure situation, 
precludes their being detected in any of the exposed populations in the European Community. 
Cancer is  well  known  as  a  late effect of radiation  exposure  and  some estimates of the cancer 
relationship  with  dose  are  available.  Given  the  exposure  situation  described  earlier,  it  is 
extremely  unlikely  that  any  study  on  the  post-Chernobyl  cancer  rates  in  adults  within  the 
Community will  produce useful  information and the Panel considers  such  a  study  to  have  no 
merit.  The study of heritable genetic effects in  the offspring of those exposed would  also  be a 
totally unproductive effort. 
Cancers in children differ from  cancers in adults in four important respects relevant to the Panel's 
task.  First, they are likely,  in the majority of instances, to be related to events that occur during 
the period of gestation.  Secondly,  they are normally so  rare and the foetus  is  so susceptible to 
radiation damage that associations have been reported following exposure of the foetus to  excess 
doses of ionizing radiation of the order of 10 to 50 mGy.  Thirdly,  the occurrence of the disease 
can be related to the area  in  which  the mother resided  during  pregnancy and  to the time  of 
birth.  Fourthly,  the disease  occurs  relatively  soon  after  birth.  For these  reasons,  the  Panel 
believes that studies of childhood cancer might offer some opportunity for detecting an effect of 
the Chernobyl accident. 
Despite the above considerations, it is the opinion of the Panel on current estimates of radiation 
risks  that even  a  study  of childhood  cancer  following  in  utero  exposure would  be unlikely  to 
demonstrate  any  attributable  increase  in  risk.  The  estimated  foetal  doses  resulting  from  the 
Chernobyl  accident  are too low  for  such  an  increase to  be reliably detected.  Moreover,  the 
complexity  introduced  by  the  need  to  allow  for  the  higher  doses  experienced  from  natural 
background radiation or medical x-rays  would  conceivably mask any possible effect or produce 
spurious findings.  Nevertheless, there is  clear public concern about the health consequences of 
increased radiation exposure from  the Chernobyl accident and it might  be possible to detect an 
effect  if  our  estimates  of risk  were  too  low  by  a  factor  of about  5.  The  Panel  therefore 
recommends,  as  a  check  on our  ability  to  predict  risks  from  doses  of the  order  received,  to 
contribute  to  our understanding  of the  occurrence  of childhood  leukemia,  and  to  allay  public 
anxiety,  that a small epidemiologic survey of childhood cancer be conducted within  areas where 
selected cancer registration was  in  existence at the time of the Chernobyl accident. 
-X-Study Design and Methodologic Considerations 
A study of the kind  that the Panel recommends  requires  the ongoing registration of childhood 
cancers, ie those occurring in early life.  As stated before, such registration must have been well 
established  before the Chernobyl  accident  in  order to  have confidence  in  the completeness  of 
registration  that is  necessary for  the study of cancer trends with  time to be interpretable.  One 
possible approach would compare childhood cancer rates in  areas of high and low exposures, or, 
if adequate  dosimetric  information  is  available,  as  a  function  of dose,  but  again,  only  if  the 
reliability of the registration data has been established before the accident occurred. 
In order to improve the statistical power of these studies, joint analysis of data sets from  different 
registration areas needs to be considered.  This, however, will  require a high degree of uniformity 
among the registration procedures, a condition that may need special efforts to accomplish,  and 
one that may be hard to meet for some of the existing registries within the European Community. 
An additional problem  is  created by  the fact  that the areas receiving the highest exposures are 
not included in  registration areas. 
For  all  of these  reasons,  it  would  not  be  advisable  to  initiate  ad  hoc  studies.  The  Panel 
recommends,  however,  that  the  Commission  give  serious  consideration  to  the  promotion  of 
comparable studies  already going  on elsewhere.  Excellent  registries  are  operated  in  countries 
outside the Community, eg in Nordic countries and in countries of Central Europe, some of which 
have  areas where exposures have been high.  The International Agency for  Research of Cancer 
(IARC) is  organising a collaborative effort for  the monitoring of childhood leukaemia in which 
particular attention is  given to comparability of registry data in  different areas.  Although much 
of the information to be obtained is  not derived from  population groups within the Community, 
the  data  obtained  should  be  considered  extremely  useful,  particularly  if  the  study  could  be 
extended to include all childhood cancer.  Finally,  close collaboration with scientists carrying out 
studies  in  the  USSR,  ie  on  people  exposed  in  areas  much  closer  to  the  accident  site  and 
therefore  much  more  likely  to  result  in  scientifically  useful  information,  ought  to  be seriously 
considered. 
-XI-Limitations 
The  Panel  is  aware  that  the  above  suggestions  are  not  easily  implemented  and  that  in  all 
likelihood  results  from  the study  envisaged  might be open to many and varied interpretations. 
In order to minimise this possibility, the Panel recommends that if any study is to be undertaken, 
it  be planned  in  detail,  with  precise  definition  of the boundaries of high  and  low  dose  areas, 
exposure and control cohorts and statistical methodology before any data are examined.  This will 
diminish misinterpretation of results which  occurred purely by  chance. 
The Panel also  recognises  that such  a study may  require a long-term  commitment and  that its 
duration  should  be  kept  to  the  minimum  required  for  obtaining  reliable  results.  As  most 
childhood cancers following  in-utero exposure  may  be expected  to occur within  a period of  8-
10 years  after exposure,  the Panel recommends  that a first  evaluation of the childhood  cancer 
cohort-specific incidence be made after five years, at which point a decision can be made whether 
to extend the observations by  another period of five  years. 
Finally,  the Panel notes that some of the difficulties of setting up  a well-designed  investigation 
arise from  the inadequacies of existing cancer registration mechanisms in  areas of high exposure 
within the Community and in comparable adjacent areas.  These inadequacies spring partly from 
inadequate  investment  - for  which  remedies  could  be  found  - but  also  from  less  tractable 
problems surrounding the release of clinical diagnoses  for  public health purposes, going beyond 
the confines of the clinical consultation.  The Panel recommends that member states review their 
arrangements for  releasing such information to qualified scientists, for defining its custodianship 
and for reconciling confidentiality with  the effective utilisation of data that may be useful for the 
detection of environmental hazards. 
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93 FEASffiiLITY OF STUDIES ON HEALTH EFFECfS 
IN WESTERN EUROPE 
DUE TO THE REACfOR ACCIDENT AT  CHERNOBYL 
Report of a Task Group for  the CEC 1.  Introduction 
The successful  control  of infectious  diseases  and  generally  improved  living  conditions  have,  in 
the  technically  developed  countries,  led  to  substantially  increased  life  expectancy.  Parallel  to 
such  improvements  there  has  been  a  growing  awareness  of health  risks  due  to  a  variety  of 
environmental,  and  diet  or life  style  related  factors.  Some of the  major factors  are associated 
with  large  risks:  tobacco  smoking  is  the  leading  cause  of  cancer  mortality  in  men,  solar 
UV-light  produces the major  part of skin  cancers,  aflatoxins  are an important cause of cancer 
in  countries were refrigeration of food  is  uncommon, exposure to asbestos has  been recognized 
as  a  grave  occupational  risk.  The  list  of  examples  could  be  extended,  and  would  include 
factors  that have been identified several centuries ago. 
The  attention  to  less  prominent  risk  factors  is  of  more  recent  origin,  and  it  reflects  the 
generally  increased  apprehension  about  global  environmental,  technological,  and  industrial 
changes.  The  need  to  consider  even  minor  risk  factors  has  been  substantiated  by 
epidemiological  investigations  which  suggest  that  the  larger  part  of all  cancers  is  due  to  a 
multiplicity of causes which  are largely unrecognized  but should  be avoidable in  principle.  This 
has  led  to  lasting debates  about the possible  role of chemical  carcinogens  and about the need 
to  keep  the  exposure  to  such  carcinogens  at  safe  levels.  Such  'safe'  levels  can  exist  only  if 
there  are  dose  thresholds  for  the  action  of carcinogens,  but  the existence  of thresholds  is  an 
unresolved  issue.  This  uncertainty has  focussed  added  attention on the study  of potential risks 
through  epidemiological  investigations.  It  has  also  made  it  necessary  to  consider  the 
acceptability  of  risks  that  are  caused  by  small  doses  of  carcinogens  in  the  absence  of 
thresholds. 
In the recent past there has been especial interest in  the mutagenic and  carcinogenic action of 
ionizing  radiations.  That ionizing  radiation  is  an effective mutagen and  carcinogen had become 
apparent  even  around  the  turn  of  the  century  when  the  first  skin  cancers  and  the  first 
leukaemias  in  radiologists  were  seen.  Nevertheless  the  knowledge  was  fragmentary  and  the 
resulting  disregard  for  the  possible  hazards  led  to  tragic  experiences  caused  by  the  use  and 
- 3  -misuse of x-rays  and of radionuclides in  industry and  medicine  (see discussion  of dial  painters, 
thorotrast  patients  and  radium-224  patients in  Annex A).  During this  period  there has  been -
in  spite of warning voices  - a general expectation of positive  effects  of small doses  of ionizing 
radiations. 
The situation changed  dramatically when  the atomic bombs where dropped on Hiroshima  and 
Nagasaki,  and when,  a  few  years  later,  a  marked  increase of leukaemias was  seen  among  the 
survivors  of the bombings. It was  then realized  that leukaemia  and  cancer in general can  arise 
from  the  mutation  or  transformation  of individual  somatic  cells  and  that,  accordingly,  there 
may be no threshold of dose for  the induction of cancer. 
It is  a  characteristic feature of ionizing  radiations  that individual  charged  particles can transfer 
substantial  amounts  of energy  to  a  cell.  The  dose  is  merely  a  statistical  average  of energy 
received  by  the exposed  tissue,  i.e.  by  a  multiplicity  of cells.  When  the dose  is  reduced,  fewer 
cells  are  traversed  by  a  charged  particle,  but  those  cells  that  are  affected  receive  energies 
which  are  independent  of  dose  and  dependent  merely  on  the  properties  of  the  charged 
particle.  This  is  an important difference  to  chemical  carcinogens  for  which  the  problem  of a 
possible threshold is  more complex.  With ionizing  radiations no dose threshold can be assumed 
for  the  mutation  of  individual  cells  and,  therefore,  for  hereditary  effects.  For  radiation 
carcinogenesis  the  absence  of a  threshold  is  a  reasonable  assumption,  although  the  situation 
may  be  complicated  due  to  radiation  induced  changes  of  the  tissue  or  of  the  immune 
response.  Such changes - if they were to occur even at small doses  - could  alter the chance of 
a  transformed  cell  to  cause  uncontrolled  growth,  and  this  could  lead  to  complicated  dose 
dependences. 
The  continued  epidemiological  investigation  of the  fate  of the  survivors  of  Hiroshima  and 
Nagasaki  has  provided  a  wide  range  of data  on radiation  induced  cancer.  At  the  same  time 
numerous  other  studies  have  confirmed  and  supplemented  the  resulting  insights.  Ionizing 
radiation  is,  by  now,  the  most  widely  studied  and  - in  spite  of remaining  uncertainties  - the 
best understood carcinogenic agent. 
- 4  -These  developments  were  paralleled  by  a  marked  reversion  of the  public  perception  of the 
risks  of ionizing  radiations.  The earlier lack of attention was  replaced by  acute awareness.  The 
concern  began  to  grow  already  during  the years  of large  scale  atmospheric  nuclear  weapons 
testing  (1950-1965),  when  the  fall-out  of the  tests  began  to  add  appreciably  to  the  general 
radiation  exposure  in  the  northern hemisphere.  The impact  was  far  greater  after  the  reactor 
catastrophe in  Chernobyl,  when  a small  part of the Soviet  Union  received  massive  radioactive 
contamination~ and  when  even  in  some  parts  of the  Western  European countries,  radioactive 
contaminations  occurred which  reached  or exceeded  the total  fall-out  during  the nuclear  arms 
testing.  Outside the immediate area of the reactor accident  the resulting doses were  too  small 
to  cause  'acute'  radiation  effects,  i.e.  effects  that  occur  and  are  observable  soon  after 
irradiation.  However,  the doses  were  large  enough,  in  some  regions  even of Western  Europe, 
to  cause  an  appreciable  increase  above  the  average  natural  radiation  exposure  in  the  year 
after  the  accident  (see  Annex  B).  In  the  first  year  after  the  accident  the  estimated  increase 
over  the  natural  exposure was  about  20%  in  the  countries  of the European  Community  (see 
Annex B).  In the five  subsequent years  the increase will  amount to an estimated 3%. 
The  unexpectedness  of  the  event  and  the  initial  uncertainty  about  the  level  of  the 
contamination  and  the  resulting  doses  led  to  extraordinary  public  anxiety  and  to  marked 
changes  of life  style  and  dietary  habits.  Administrations  and  experts  succeeded  only  partly  in 
informing  the public  and  in  avoiding  the  impression of widely  contradictory measurements and 
interpretations.  Even  now,  after  many  of the  seeming  contradictions  have  been  resolved  and 
doses  due to  external  and  internal exposures  are  known with  some  accuracy,  there are lasting 
concerns  and  continued  requests  to  perform  investigations  that  might  contribute  to  an 
assessment  of  possible  health  effects  of  the  radioactive  contamination  after  the  reactor 
accident. 
The need and  the feasibility of an epidemiological follow-up  investigation of the evacuees  from 
the  immediate  surrounding  of Chernobyl  are  apparent.  There  is  international  agreement  that 
every effort should  be made to  perform  such  studies  and  to  guarantee their continuation over 
- 5  -several  decades.  The  group  of evacuees  comprises  about  35000  people  who  received  doses 
around 0.4  Gy,  which  is  100  to  1000  times  larger than the exposures  resulting  from  Chernobyl 
in  even the most highly contaminated regions of Western Europe (for details see Annex B). 
It  is  a  much  more  difficult  question  whether  epidemiological  investigations  should  be 
performed  in  the  far  larger  populations  of  Europe  which  were  exposed  to  much  lower 
increments  of their usual exposures.  In spite of the difficulty,  the question  needs  to be asked, 
and it  is  the purpose of the present document to contribute at least partial answers. 
The great public concern and the need for  a broad consensus in  any  resulting decision make it 
necessary  to  treat the  problem  in  a  way  which  is  intelligible  even to the nonspecialist.  In the 
subsequent  introductory  chapters  some  essential  facts  about  ionizing  radiations  and  their 
biological  effects  are  given.  Although  the  treatment  is  brief,  it  may  facilitate  general 
understanding and the access  to sources of more detailed information. 
- 6  -ii 
2.  Exposure to Radiation 
2.1  Exposures from  Internal and External Sources 
There are various  types  of ionizing  radiations.  They differ  in  their ability  to  penetrate exposed 
objects,  and  they  differ  in  the  amount of energy  that individual  charged  particles  impart to  a 
cell.  However,  the  principal  underlying  mechanisms  are  the  same.  The  most  commonly 
encountered  radiations  are x-rays  or gamma  rays;  they  consist of photons  (i.e.  electromagnetic 
quanta)  with  energies  that  are  large  compared  to  the  binding  energies  of electrons  which 
determine  the  structure  of molecules  or  biomolecules.  The  photons  can  penetrate  the  body 
and  can  release  in  the  body  energetic  electrons  which  have  comparatively  short  ranges  of a 
few  mm,  but which  can in  turn - while  they traverse the cells  of the body - liberate thousands 
of further,  less  energetic  electrons.  Electrons  can  also  be  emitted  directly  by  a  radionuclide 
which  is  then  called  a  B-emitter,  and  the  resulting  molecular  mechanisms  are  the  same 
whether the electron  is  released  by  a  photon or by  a radionuclide.  Any  release of an  electron 
from  a molecule is  called ionization.  Not all  the molecular changes of the DNA resulting from 
ionizations  are  correctly  repaired  by  the  cell,  and  the  remaining  damage  can  impair  or alter 
the  cellular  functions.  It is  important  to  realize  that  the  photons,  by  themselves,  have  no 
biological  effects,  but  that  they  act  merely  by  producing  a  'secondary'  radiation  within  the 
body,  i.e.  the high energy recoil electrons. 
The failure  to understand the role of the recoil  electrons has  led  to lasting confusion after the 
reactor accident, when  radiation exposure due to  incorporated  radioactive caesium was  held  to 
be  of  entirely  different  quality  than  exposure  from  external  caesium.  In  fact,  there  is  no 
difference  in  principle  between  the  action  of external  and  internal  exposure.  Incorporated 
caesium  is  distributed  nearly  uniformly  throughout  the  body  and  it  produces  through  the 
emitted B- and gamma-rays  a general exposure of all  tissues  and  organs.  The same occurs,  due 
to  the  fairly  high  penetrating  power  of the  caesium  gamma  rays,  when  the exposure  is  from 
the outside. After the decay of a caesium  atom,  either outside or within  the body,  the released 
photon  traverses  a  substantial  distance  and  then  sets  into  motion  an  energetic  electron;  this 
- 7 -process  is  entirely the same,  regardless  of whether the photon had  originated within  the body 
or outside.  Incorporated caesium  produces a continuous exposure,  until it  is  removed from  the 
body,  with  a  biological  half  life  (mean  excretion  time)  of  about  80  days.  A  continuous 
exposure  results  equally  from  caesium  in  the  environment.  This  external  exposure  decreases 
much  more slowly  in  time because part of the caesium  can remain for  years  in  the superficial 
layers  of the soil  and  can,  therefore,  contribute to  the terrestrial gamma  ray  intensity  until  it 
decays with  its  physical  half life of 31  years.  Caesium  is,  therefore, to be regarded as  a general 
radiation hazard to all  tissues  of the body,  whether its  effect is  exerted externally or internally, 
and  any  increase  in  specific  cancers  would  be related  to  the  varying  radiation  sensitivities  of 
the  different  organs  and  tissues,  rather  than  to  the  location  of  the  caesium  itself.  The 
equivalence  of external  and  internal  exposures  implies  the  equivalence  of equal  doses  from 
external sources  and  from  sources  through  the food  chain  (for  quantities  and  units  see Annex 
E).  It  is  merely  a  matter  of  appropriate  dose  calculation  procedures  to  evaluate  each 
contribution  correctly,  including,  for  example,  the  contribution  of B-rays  ('v50%)  for  internal 
caesium  exposure  and  excluding  this  component  for  external  exposure  because  of the  short 
range of the electrons. 
2.2  Organ Specific Exposures 
There are,  of course,  specific  effects  of incorporated  radionuclides,  when  these concentrate in 
individual  organs.  The most  critical  organ  seeking  radionuclides  after a  release  from  a  reactor 
are  iodine,  and  strontium.  Strontium  is  a  'bone seeker'  of long  half life,  and  it  was  a  major 
contributor  to  possible  health  detriments  in  the  fall-out  from  nuclear  weapons  testing.  The 
radioactive  contamination  in  Europe after  the reactor catastrophe  in  Chernobyl,  on the other 
hand,  contained  comparatively  little  strontium  and  it  added  only  a  minor  increment  to  the 
contamination which  has  remained from  nuclear weapons testing.  Strontium was,  therefore,  not 
a nuclide of major concern after the reactor accident. 
- 8 -Radio-iodine,  however,  has  been of special  concern  because  high  activities  were  released  and 
have  reached  Western  Europe.  The  iodine  is  effectively  accumulated  in  the  thyroid  and  can 
cause  substantial  radiation  doses  in  this  organ  (see  Annex  B).  Due to  the short  physical  half 
life  of the critical  nuclide,  1-131,  (about 8  days)  the  period  of concern was  limited  to  several 
weeks.  But  in  the  initial  phase  immediately  after  the  reactor  accident,  1-131  has  been  the 
critical  radionuclide  of predominant  concern;  with  unreduced  consumption  of contaminated 
vegetables  and  milk,  thyroid  doses  of up  to several  tens  of mGy  may  have been reached even 
in  the  Western  European  countries.  The  doses  due  to  caesium  were  much  lower,  and  were 
unlikely  to exceed  about 1 m  Gy  in  the first  year even in  critical  groups;  however  the caesium 
led  to an almost uniform  exposure of the whole body. 
Summarizing these considerations one can say  that the radionuclides of main concern after the 
Chernobyl  accident  are  iodine which  can  affect  the  thyroid,  and  caesium  which  can  affect  all 
organs  of the  body.  An  assessment  of the  magnitude  of doses  from  these  radionuclides  for 
different  levels  of  contamination  is  given  in  Annex  B.  In  such  considerations  one  must 
distinguish  between  ori!an  doses  and  whole  body  doses.  As  a  rough  measure  of comparison 
one may  note that a whole body dose  is  assumed  to  carry a cancer mortality risk  that is  about 
30  times larger than a thyroid  dose of the same magnitude (see Annex E). 
2.3  Natural Radiation Exposure 
Exposures  from  the  radioactive  contamination  after  the  accident  can  usefully  be  compared 
with  the  magnitude  of doses  from  natural  exposures.  The  natural  radiation  exposure  results 
from  terrestrial  gamma  radiation,  cosmic  radiation,  and  from  irradiation  due  to  radioactivity 
always  present in  the human  body  (mainly  about 60  Bq!kg  of K-40).  The inhalation  of radon 
and its  radioactive decay products accounts for  an additional important contribution. 
The  total  annual  dose  from  these  three  contributions  - not  including  the  contribution  from 
radon  - is  about  1  mGy,  but  it  may  vary  substantially  according  to  the  different  levels  of 
- 9  -terrestrial  gamma  radiation.  In  certain  parts  of the  world,  and  also  in  parts  of the  member 
states  of the  European Community,  the natural radiation  exposure  is  more  than doubled  due 
to  higher  terrestrial  gamma  radiation.  There  are  also  substantially  larger  doses  in  regions  of 
higher  altitude  because  of the enhanced  cosmic-ray  intensity.  The inhalation  of radon  and  its 
decay  products  in  houses  adds  to  the  quoted  dose;  it  results  in  an  a-ray  dose  to  the  lung, 
commonly  in  excess  of 0.5  m  Gy,  and  in  not infrequent instances  in  excess  of 5 m  Gy  per year. 
Using  the applicable weighting  factors  for  the lung  (w  = 0.12)  and  for  a-radiation (Q  = 20) 
(see  Annex  E) one concludes  that the contribution of radon in  houses  equals  on the average 
approximately the contribution of the remainder of natural radiation exposure. The total whole 
body dose during a lifetime due to the natural sources amounts to about 100 mGy. 
The contribution to the exposure of the population due to  medical diagnostic  procedures adds 
- in  the  European  countries  - another  dose  averaged  over  the  population  and  the  organs  of 
the body of about 0.5  m  Gy  per year. 
- 10  -3.  Radiation Effects 
3.1  Acute (Early) Effects 
Absence of Acute Effects: 
Large  doses  of radiation cause  massive  cell  killing  and  radiation  syndromes  which  are termed 
acute effects.  The severity  of these effects  is  dependent on the dose  of radiation,  and  after  a 
whole  body dose of several gray  the exposed  person may  die.  Moderate doses  of radiation,  or 
larger  doses  to  localized  tissues  or  individual  organs,  as  they  are  employed  in  therapy,  can 
produce various dose related effects, such  as  inflammation, scarring, or tissue atrophy. 
Acute  radiation effects  with  dose  related  severity  are analogous  to  effects  from  other physical 
agents  such  as  burning or chemical  poisoning.  For instance,  prenatal exposure with  sufficiently 
large  doses  can  cause  extensive  cell  killin2  in  the  developing  embryo  or foetus,  and  this  can 
lead  to  abortions  or can damage  the developing  brain.  For  acute effects,  there is  a  threshold 
dose  below  which  the  effect  is  seldom  or never  detected.  These  effects  are  not  of concern 
with  regard  to  the  radioactive  contamination  produced  in  countries  of  the  European 
Community  after  the  Chernobyl  accident.  The  resulting  doses  were  far  below  those  required 
for  acute effects. 
3.1.1  Malformations 
The majority of con2enital  malformations  are not demonstrably due to  simple  specific  genetic 
disorders,  although  some  of them  show  familial  concentrations  and  some  (e.g.  cleft  palate) 
offer evidence  that abnormal  genes  may  play  a  part.  Most  of the malformations  are probably 
caused  by  environmental  factors,  or  are  due  to  complex  random  combinations  or 
re-assortments of genes which  in  other cirumstances would  individually  be regarded  as  normal. 
One must nevertheless consider the possibility that radiation damage to  the genetic material of 
the  early  embryo,  possibly  before  implantation,  could  cause  an  irreparable  re-direction  of 
- 11  -development. The major concern,  however,  must be malformations,  due to  massive  cell  killing; 
but  these  are  acute  effects  with  a  threshold  dose  and,  therefore,  most  unlikely  to  occur  at 
small doses. 
3.1.2  Mental Retardation 
There is  one special effect  that is  related  to  cell  killing  but can occur  at relatively  low  doses. 
This  effect  is  mental  retardation caused  by  irradiation  of a  foetus  especially  between  the 8th 
and  the  15th week  after  conception.  Among  the children who  were  exposed  in  utero  by  the 
atomic  bombs  in  Hiroshima  and  Nagasaki  there  was  an  increased  frequency  of  mental 
retardations,  and  it  was  recognized  that  most  of the  mentally  retarded  were  exposed  during 
the critical  period  (8th  to  the 15th week post conception) which  is  associated  with  a wave  of 
proliferation  and  of migration  of neural  precursor  cells.  The  statistical  analysis  of the  data 
suggested  that there need not be a  threshold  in  the dose dependence,  and a  risk  factor of 0.4 
per Gy (Tab.1) has been estimated.  Determinations of the IQ-values of the prenatally exposed 
children  were  cited  in  support  of this  conclusion.  However,  it  was  also  pointed  out  that  a 
threshold cannot be excluded.  Regardless of this  unresolved question it  must be noted that the 
high  sensitivity  had  not  been  expected  earlier,  and  that  it  requires  special  caution  in  the 
avoidance of exposures of the foetus  during the critical period. 
3.2  Late Effects 
Of main  concern,  with  regard  to  low  doses,  are  the so-called  late or long-term  effects  which 
result from  the mutagenic action of ionizing radiation and which  can become manifest years  or 
decades  after  the  irradiation.  The  main  effects  of  this  type  are  hereditary  damages  and 
cancers.  The  probability  for  the  effect  depends  on  dose  but  the  severity  does  not.  The 
response  to  radiation  is  thus  of  an  ali-or-none  character;  those  who  escape  are  entirely 
unaffected.  One cannot exclude  that some of these effects  have  a  dose  threshold below which 
- 12  -they  are  not  induced.  But  there  is  no  actual  evidence  for  such  thresholds,  and  it  appears 
certain  that  there  can  be  no  threshold  for  radiation  induced  mutations  of cells  which  are 
responsible  for  hereditary damage and,  at least partly,  responsible  for  radiation carcinogenesis. 
For radiation protection it  is,  therefore,  generally  assumed  that there is  no  threshold  and  that 
any  dose,  however small,  will  carry a  correspondingly small  risk of late effects.  One must  note 
in  this  context  that  there  is  an  emerging  consensus,  even  among  toxicologists,  that  no 
thresholds of dose or concentration exist  for  the genotoxic actions of chemical mutagens either. 
The  cancers  and  genetic  effects  induced  by  radiation  exposure  are  indistinguishable  from 
cancers  and  genetic effects  occurring without radiation exposure.  They cannot be attributed  to 
irradiation  in  an  individual  case.  The  effects  of the  radiation  are  manifest  only  in  increased 
incidence  rates  in  exposed  groups.  Characteristically,  the increased  incidence  rates  occur  after 
a prolonged interval of time,  from  several years  to several decades after exposure. 
For the  purposes  of the  present discussion  and  for  small  doses  we  will  utilize  the  assumption 
of linear  dose  dependences  in  the sense  of a  conservative  estimate.  An implication  is,  that  a 
given  dose  causes  the  same  number  of disease  events  (e.g.  cancers),  no  matter whether  it  is 
evenly  or unevenly  distributed  across  the  population.  The  exposure of a  population  can  then 
be characterised by  the collective dose which  is  the sum  of doses  received by  individuals  of the 
population. Accordingly,  the collective dose  (stated in  units  of personGy)  is  the product of the 
mean individual dose and  the number of individuals concerned. 
In the case of the Chernobyl accident,  and  except for  people exposed  in  the immediate vicinity 
of the disaster,  late effects  are the only ones which  one might  possibly  attempt to  detect. That 
is,  we  must  look  for  changes  in  the incidence  rate of disorders  already  known  to  be radiation 
related.  We should  not expect  that radiation  syndromes  or other acute  effects  (e.g.  cataracts) 
have  occurred.  Nor  should  we  expect  to  detect  any  diseases  which  are  specifically  related  to 
radiation,  and which  could serve as  a unique marker of its  presence. Furthermore, although we 
should  keep  an open mind  on the matter, we  should  not expect  to  detect previously  unknown 
radiation effects. 
- 13  -3.2.1  Cancer 
The major  risk  of small  doses  of ionizing  radiation  is  carcino2enesis.  It is  well  known  from  a 
variety  of studies,  and  chiefly  from  the  fate  of the  survivors  of the  atomic  bombings,  that 
radiation can induce most cancers  and,  especially,  leukaemias.  The increased  frequencies  have, 
in  the majority of these studies,  been found  for  persons exposed to relatively high doses  of the 
order of some 100 mGy or more.  Any extrapolation to  low doses  must,  therefore, be based on 
hypotheses.  For the puposes of the present study linear extrapolations  (see solid  line  in  Fig.l) 
will  be  utilized.  But  a  variety  of  radiobiological  investigations  suggest  that  actual  dose 
dependences are linear-quadratic (broken line  in  Fig.l) with  correspondingly decreased  risks  at 
low  doses.  Other forms  of the dose-effect relation can also  not be excluded.  However,  there is 
no  apparent  reason  to  believe  that  there  should  be  a  threshold  at  low  doses  below  which 
malignancies  cannot  be induced  by  ionizing  radiations.  The  important  role  of somatic  muta-
tions  for  the  induction  of  cancer  is,  in  fact,  an  argument  for  the  prudent  - if  possibly 
conservative  - assumption  of linearity  down  to  low  doses.  Radiation  induced  changes  in  the 
tissue  response  to  a  transformed  cell  or in  the  response  of the  immune  system  could  occur, 
but they may be unlikely at very low  doses. 
The important  role  of cellular  repair  processes  might  suggest  that  there  needs  to  be a  dose 
threshold,  but this  assumption would  be fallacious  because it  presupposes  fully  efficient  repair 
in  unirradiated  cells  or in  cells  exposed  to  low  doses.  In  fact  it  is  known  that cellular  repair 
processes,  while  highly  effective,  are  never  free  from  a  certain  probability  of  misrepair. 
Mutations  and  possibly  a  resultant  loss  of growth  control  are  the  result  of such  misrepair.  If 
the  probability  of misrepair  is  substantially  unaltered  at  small  doses,  there  is  no  reason  to 
expect dose thresholds;  one will,  instead, obtain linear dependences on dose at low  doses. 
There is,  on the other hand,  great interest  in  the study  of any  possible  effect  that even  small 
doses  might  have  on  the  repair  systems,  and  one  may,  therefore,  note  certain  preliminary 
evidence  that  small  doses  may  activate  repair  systems  which,  in  turn,  enable  the  cell  to 
respond  to  subsequent  (radiation  induced)  damages  more  effectively.  Such  effects  could  alter 
- 14  -considerably  the  dose-effect  relations,  and  they  would,  therefore,  be  highly  relevant  to  the 
estimation of risks  from  low  doses.  Current research in  radiation  biophysics  and  epidemiology 
deals with these phenomena, but it  has  not, as  yet,  led to definite conclusions. 
Radiation  induced  tumours  cannot  be  recognized  directly  because  they  do  not  differ  from 
spontaneous  tumours.  The  statistical  proof,  on  the  other  hand,  of  increased  rates  in  a 
population is  difficult  because the tumours  occur years  or decades  after an exposure.  One has 
to  observe,  at least in  principle,  the total life  span of all  members of an irradiated group  and 
register  all  cancer cases.  In  most  investigations  this  is  not  feasible,  and  certain  basic  assum p-
tions  about the temporal course of the tumour  incidences  must,  therefore,  be utilized,  even if 
the observation span covers  several decades. The required extrapolations  are based on lifetime 
risk  projection models which  differ for different types  of tumours. 
For  a  variety  of cancers,  mortality  rates  - and  in  some  instances  also  incidence  rates  - have 
been estimated  as  a  function  of dose,  of sex,  of age  at exposure,  and  of time  after exposure. 
Some of the essential points will  be considered. 
3.2.1.1  Solid Cancers 
From  the available  data one may  conclude  that radiation enhances  the  rates  of solid  tumours 
(all  cancers  except  leukaemia)  in  such  a  way  that  they  run  proportional  to  the  spontaneous 
age  specific  rates  (see  Figs.  2 and  3);  bone sarcomas  do  not seem  to  follow  this  pattern.  The 
enhancement  factors,  i.e.  the  rates  in  the  exposed  divided  by  the  rates  in  the  non-exposed 
(relative  risks),  are  different  for  different  tumours  and  they  depend on  dose,  on sex,  and  on 
age  of exposure  (in  general  they  are  higher  for  younger  ages  at exposure).  According  to  the 
relative  risk  model  they do  not depend on time  after exposure  (after a  latency period  of 5 to 
10 years).  Lifetime risk  projections are often obtained on the basis  of this  model. 
- 15  -The relative risk  model has been used in  the most  recent risk estimates for  solid  tumours after 
the revision  of the atomic bomb dosimetry  (Annex A,  Fig.A.1).  Averaged  over all  ages  a dose 
of about 2  Gy  is  estimated to  double  the cancer rates;  such  a dose would,  therefore,  increase 
the lifetime cancer-death risk  from  its  present value of about 0.2 to a value of 0.4. 
A dose of 2 Gy  to  double the cancer rates  corresponds  - if one uses  the linear extrapolation 
to  low  doses  - to  a  mortality  risk  factor  for  solid  cancers  of about  0.1/Gy  (1000  cases  per 
10000  persons  per  Gy).  This  is  substantially  larger  than  estimates  which  have  earlier  been 
employed by  BEIR, UNSCEAR and ICRP (partly due to  different premisses),  and  which  have 
contained  an  assumed  reduction  factor  for  low  dose  and  low  dose  rate.  For  the  subsequent 
estimations  in  this  document  a  purely  linear  extrapolation  to  small  doses  is  employed,  and  a 
risk  factor  of 0.1/Gy  for  all  solid  tumours  combined  is  used  as  an  average  for  all  ages  at 
exposure (Tab.1  and Annex B,  Tab.B.3).  Even if the estimate is  conservative,  it provides  useful 
general guidance. 
3.2.1.2  Leukaemias 
For  leukaemias  the  situation  is  different  (Fig.2).  Among  the  survivors  from  Hiroshima  and 
Nagasaki,  and  also  among  patients  treated  with  x-rays  for  ankylosing  spondylitis,  leukaemias 
have  occurred  in  a  characteristic  wave  of increased  frequencies.  These  waves  reach,  after  a 
short  latency  of about 2  to  5 years,  a  maximum  5  to  10  years  after exposure.  The increased 
rates  disappear largely  after about 20  to  25  years  (Fig.3).  Such  temporal dependences  that do 
not  parallel  the  spontaneous  age  specific  rates  are  referred  to  by  the  term  absolute  risk 
model.  Fig.3  indicates  the  characteristic  differences  between  the  absolute  risk  model  for 
leukaemia  (and bone sarcoma) and of the relative risk  model for solid cancers. 
From  the  absolute  risk  model  it  follows  that  most  radiation  induced  leukaemias  among  the 
atomic  bomb  survivors  have  already  occurred.  This  is  in  sharp  contrast  to  the  situation  with 
solid  tumours  where  - according  to  relative  risk  model  - a  large  fraction  of  the  radiation 
- 16  -induced solid  tumours is  still  to occur,  especially among those exposed  at younger ages.  Today, 
four decades after the beginning of the epidemiological studies in Hiroshima and Nagasaki,  the 
projection of future excess  cancer cases  is  still  a central issue  for  solid  tumours. The projection 
of future  cases  is  of  minor  importance  for  leukaemias  which  follow  the  specific  temporal 
course characteristic for  the absolute risk model (Fig.3  and Annex A). 
According  to  the new  risk  assessment,  the doubling  dose  for  leukaemia - again  averaged  over 
all  ages  at exposure  - is  approximately  0.7Gy  (spontaneous  life  time  rate:  about 0.007)  which 
is  less  than  the  doubling  dose  for  solid  tumours.  However,  the  relative  risk  model  has  little 
meaning  for  leukaemias;  it  is  more  appropriate  to  state the estimated  absolute  risk  factor  of 
about 0.01/Gy. 
3.2.2  Cancer in Children 
Cancer in  children has  been shown  to  be correlated with radiation exposure,  including  medical 
diagnostic exposures  and  therapeutic irradiations.  There is  also  evidence of a  high  sensitivity of 
children to radiation exposure with  respect to cancers which  occur many years  later,  i.e.  during 
adulthood.  In  a  few  studies  increased  cancer  frequencies  have  been  found  even  at 
comparatively  low  doses  (see  Annex  A).  One  example  of the  sensitivity  of children  is  the 
finding  of increased  thyroid  cancer  rates  in  a  follow-up  study  of children  whose  heads  were 
irradiated with  x-rays  for  the  treatment of tinea  capitis  (ring  worm  of the scalp).  In this  study 
the  estimated  average  dose  to  the  thyroid  was  less  than  100  mGy;  the  thyroid  cancers 
occurred  many  years  after  the  exposures  and  they  paralleled  the  rise  of age-specific  cancer 
rates. 
From  the follow-up  of the  atomic  bomb  survivors  one cannot yet  infer  reliable  absolute  risk 
estimates  for  those  who  were  exposed  as  adolescents  or  children;  there  are  still  no  precise 
data  for  the  late  occurring  solid  cancers.  But  it  has  become  clear  that  the  relative  risks,  i.e. 
the  radiation  induced  rates  of cancer  in  relation  to  the  spontaneous  rates,  are  substantially 
larger for  those exposed  at young  ages. 
- 17  -For  childhood  tumours,  and  especially  for  the  leukaemias  which  occur  early  after  exposures 
during  childhood  the  relative  excess  risks,  i.e.  the  rates  of radiation  induced  to  spontaneous 
cases  are particularly  high.  Among  the children  exposed  to  the  atomic  bomb  radiation  about 
12  excess  leukaemias  were  observed.  This  corresponds,  under  the  assumption  of linearity  in 
dose,  to  a  risk  factor  of about 0.01/Gy.  This  is  roughly  the same absolute  excess  rate  as  that 
estimated  for  adults,  but it  is  a  much  higher  relative  excess  over the low  spontaneous rate in 
childhood.  A  dose,  due  to  the  reactor  accident,  of  1mGy  will  nevertheless  not  lead  to 
observable increases;  it  may enhance the spontaneous risk of about 3-10-4  to develop leukaemia 
between age 0 and  10  by  roughly 3%;  such  an increase  is  certain to remain undetected in  any 
epidemiological survey. 
The  situation  might  be  different  for  childhood  cancers  due  to  prenatal  exposures.  But  for 
these  cancers  there  are widely  diverging  risk  estimates.  Among  920  children  exposed  in  utero 
in  Hiroshima  and  Nagasaki  with  doses  in  excess  of  10  m  Gy  no  leukaemia  cases  were 
registered.  The average  dose  in  these  prenatally  exposed  children  was,  according  to  the  new 
dosimetry,  only  0.25  Gy.  A  risk  estimate  of 0.01/Gy  would,  therefore,  correspond  to  about  2 
expected  cases.  Even  a  threefold  higher  risk  estimate of 0.03/Gy  cannot be excluded,  because 
it would correspond to only 6 expected cases,  and this  could  have remained unobserved due to 
statistical  fluctuations  and  due  to  a  lack  of observations  in  the  immediate  years  after  the 
bombings. 
Childhood cancers were studied  in  some recent re-evaluations of data from  the 'Oxford Survey 
of Childhood  Cancer'  (OSCC)  which  indicated  substantially  increased  cancer  rates  in  children 
prenatally  exposed  (for  diagnostic  purposes)  with  x-ray  doses  estimated  to  be  about  5  to 
10mGy.  The  results  can  be  seen  as  evidence  that  prenatal  sensitivity  for  radiation  induced 
cancer  exceeds  postnatal  sensitivity.  Estimates  of the  probability  of childhood  leukaemia  of 
about  0.07 /Gy  and  of a  probability  of all  fatal  childhood  cancers  of 0.2/Gy  were  derived  for 
prenatal  exposures  (Annex  A,  (A16,  A17)).  The estimated  childhood  leukaemia  risk  appears, 
as  stated,  twice  as  large  as  maximum  values  compatible with  the observations  on the children 
exposed  in  utero in  Hiroshima  and  Nagasaki.  The overall  childhood  cancer estimate of 0.2/Gy 
- 18  -is  even  more  debatable;  it  has  not  been observed  among  the children  exposed  as  foetuses  in 
Hiroshima and  Nagasaki,  and it  should have been observed if the value were genuine. Thus,  in 
order  to  assess  the  feasibility  of epidemiological  studies  in  the  European  countries  after  the 
Chernobyl  accident,  the  risk  estimate  of  0.1/Gy  for  prenatally  induced  childhood  cancer 
(leukaemias  and  solid  tumours  between  age  0  to  10  years)  will  be utilized  (Tab.1).  It can  be 
compared  to  a  'spontaneous'  probability  of fatal  childhood  cancer  of about  10·3  (one  case  in 
1000  children younger  than  10 years),  and  it corresponds,  with  these assumed  numbers,  to  the 
very low  dose of about lOmGy  to double the spontaneous incidence. 
The  short  and  narrow  latent  intervals  and  the  high  ratios  of induced  to  spontaneous  rates 
make childhood malignancies  the evident target of potential research efforts  (Sect.4.2). 
3.2.3  Genetic Effects 
Genetic  effects,  i.e.  hereditary  effects,  are  disorders  produced  through  damage  of DNA  in 
germ  cells  and  through  the  resulting  mutations.  While  dominant  mutations  may  appear fairly 
quickly,  recessive  mutations  may  take  several  generations  to  manifest  their  ultimate  effects. 
Almost all  specific dominant and recessive disorders are rare. 
The  only  disorders  of  sufficient  frequency  to  be  investigated  within  a  short  period  after 
exposure  are  those  recognizable  as  karyotype  disorders,  i.e.  as  wrong  chromosome  numbers 
due  to  faulty  germ  cell  division,  or  due  to  abnormal  chromosome  structures  (chromosome 
fractures,  and  irregular  rejoining).  Down's  syndrome  (trisomy-21)  is  the classic  example  of the 
former case but is  unlikely  to be a radiation-related disorder.  Chromosome rearrangements are 
dose-related and are readily identifiable. 
For  hereditary  effects  no  threshold  can  be  assumed  below  which  the  induction  probability  is 
zero.  This  applies  generally  for  genotoxic  effects  of mutagens,  but  it  is  especially  evident  for 
ionizing radiations, since even individual  charged  particles can transfer considerable amounts of 
- 19  -energy to the cell  and  can,  therefore, individually cause substantial damage.  At sufficiently low 
doses  the  number of cells  affected  is  proportional  to  dose,  and  each of the  affected  cells  is 
traversed by only one charged particle. 
On the other hand,  one has  not  found  in  man direct  evidence  of hereditary  damage  due to 
irradiation.  Even  extensive  efforts  have  failed,  up  to  now,  to demonstrate significant  increases 
among  the  children  of those  exposed  to  the  radiation  from  the  atomic  bombs.  However,  in 
view  of  the  size  of  the  population  examined  and  the  doses  to  the  parents,  recognizable 
increases  were  unlikely.  While  there  is  no  doubt  that  radiation  induces  hereditary  damage, 
quantitative  estimates  must,  at  present,  be based  on animal  data.  From  such  data  one infers 
that the doubling  dose  for  hereditary damage lies  between 0.5  and  2  Gy.  This  corresponds  to 
a  risk  factor  for  genetic  disorders  of about  0.01/Gy  (Tab.  1  ).  However,  there  is  considerable 
uncertainty how multifactorial diseases may be enhanced due to radiation exposure. 
3.3  Indirect Effects 
It is  not  always  recognized  that some  measures  to  reduce  doses  after the  Chernobyl  accident 
may  have  been  harmful  by  themselves.  For  example,  iodine  salts  were  taken  in  order  to 
saturate  the  thyroid  gland  and  to  prevent  the  further  uptake of radioiodine,  and  this  carried 
some  risk.  It is  well  known  that an  abruptly increased  administration of supplementary iodine 
may  provoke  the  incidence  of  thyrotoxicosis  (hyperfunction  of  the  thyroid)  in  populations 
suffering previous iodine deficiency. 
Anxieties  after  the  reactor  catastrophe  have  induced  various  changes  in  lifestyle  and  dietary 
habits  in  the  general  population  that  can  have  ill  effects.  Nutritional  changes  or  increased 
tobacco  and  alcohol  usage  are  obvious  examples.  Other  deleterious  effects  were  pregnancy 
terminations,  or,  possibly,  untoward  effects  on  pregnancies  by  anxiety  or  changed  living 
patterns.  Further  consequences  included  suicides  and  para-suicides,  the  consumption  of 
anxiolytic drugs,  and enhanced frequency of depressions. 
- 20  -4.  Research  Tar~ets 
In identifying  attainable  research  targets  the following  points  need  to  be considered.  First  one 
must recognize  that it  is  neither possible nor desirable to attempt a direct measurement of all 
the health consequences of the Chernobyl discharges.  Even if such measurement were possible, 
the  inquiry  would  last  so  long  that  it  could  not  provide  practical  guidance  on  radiation 
protection or on energy production policies.  Assessment of these kinds can only be based upon 
existing  knowledge  and  existing  models,  modified  through  current  research,  and  not  upon 
direct determinations. 
The research  strategy must  therefore be directed  towards  the measurement of selected  health 
effects:  those which will  be detected and measured  unambigously and with  reasonable accuracy 
within  a  reasonably  short  period  of time  and  those  which  enhance  the  theoretical  basis  of 
decision making. 
The value  of the  results  we  seek  is  in  part  to  support  statements  of reassurance  concerning 
the  effect  of  the  Chernobyl  accident  itself,  and  it  is  partly  for  this  reason  that  we  shall 
recommend some inquiries  although we  expect their results  to be negative.  However,  the main 
value  of  the  results  is  scientific,  helping  to  set  upper  limits  to  the  still  uncertain  current 
estimates  of  the  relationships  between  environmental  radioactive  contaminations  and  the 
disease  risks  which  follow.  These  estimates  provide  an  essential  basis  for  public  health 
planning,  including  the formulation  of energy  policies,  the definition  of permissible  radioactive 
discharges,  and  the setting  of hazard-warning  levels.  They  provide equally  important guidance 
for  emergency action in the case of future  accidents. 
In  identifying  appropriate  research  targets,  we  have  also  examined  resource  costs.  As  it  now 
appears,  this  issue  hinges  chiefly  upon  the  quality,  location  and  scope  of  existing  health 
monitoring facilities  and  skills.  Requirements for  supplementary investment are therefore quite 
limited,  and  the  added  expenditure can even  have  positive  spin-offs  for  other problem  areas. 
However,  questions  will  be  raised  regarding  the  adequacy  of existing  facilities  and  methods, 
- 21  -and  whether  they  should  be enhanced  to  meet  requirements  that  may  arise  after  any  future 
accidents. 
Firstly,  although  possible  health  effects  of Chernobyl  may  take  some  years  to  emerge,  their 
elucidation  demands  immediate  planning  and  immediate  implementation  of  a  research 
programme.  It  is  necessary  to  define in  advance  the geographic  zones,  the  age  groups  of the 
population,  and  the  health  criteria  through  which  one  can  achieve  comparisons  between 
different  groups.  One needs  to  take  immediate  steps  to  avoid  substituting  what  should  have 
been  'prior'  declarations  by  choices  made  after  one  has  seen  the  results.  If this  is  not  done 
there  is  the  risk  of attributing  spurious  interpretations  to  the  fluctuations  that  are  bound  to 
arise  and  that are purely random  in  nature. 
4.1  Cancer in Adults 
Cancer  induction  is  seen  as  the  major  hazard  of small  doses  of radiation.  In  the  follow-up 
study  of  an  irradiated  population  most  radiation  induced  cancers  would  occur  in  adults. 
However,  the increased cancer incidences  are not readily detected;  even with  the atomic bomb 
survivors  who  were  subjected  to  high  doses  it  took  decades  of different  studies  to  detect  any 
enhanced  rates of solid  tumours and  to  quantify them  in  continued observation. The follow-up 
of 76  000  persons  led  to  the  conclusion  that  about  340  excess  cancer deaths  were  caused,  in 
1985,  among a total number of about 6 000  cancer deaths. This  represents the excess  mortality 
in  1985  and  the  number  is  likely  to  increase.  It  is  evident  that  it  must  be  difficult  or 
impossible  to  detect  enhanced  rates  among  populations  subjected  to  exposures  that  were 
several  orders  of  magnitude  smaller.  The  difficulty  is  largely  due  to  the  high  rate  of 
spontaneous  tumours  or tumours  induced  by  a  multitude  of known  or unknown  factors.  Any 
radiation  effect  is  difficult  to  recognize  against  this  background  rate.  In  addition,  the  latent 
intervals  between  exposure  and  the  occurrence  of solid  tumours  in  adults  are  relatively  long 
(in  the order of 10  to 30  years  or more)  and variable;  cancers  resulting  from  a  transient wave 
of initiations are thus widely spread out in  their appearance times. 
- 22  -The collective  dose  resulting from  Chernobyl is  estimated as  about 60000  personGy during the 
first  year  after  the  accident  for  the  entire  population  of  the  European  Community  (320 
millions).  This  corresponds to an overall  average dose of only about 0.2  mGy  (Annex B).  With 
an assumed  3 times  larger dose accumulation over 50 years  a collective dose of nearly 200  000 
personGy will  be  reached.  The  risk  estimate for  cancer  mortality  of 0.1/Gy  could  be used  to 
infer  a  hypothetical  number  of 20  000  added  cancer  deaths  within  the  population  of the 
European community due to  the Chernobyl  release.  While  formally  correct and while  correctly 
indicating that the reactor catastrophe had grave environmental consequences,  the computation 
of a  possible  number  of deaths  can,  nevertheless,  be  grossly  misleading.  The  reason  is  that 
such  numbers  suggest  - at  least  to  those  who  are  unfamiliar  with  population  statistics  - a 
tangible  threat  to  the  individual  and  a  substantial  increase  of prevailing  cancer  rates.  Both 
suggestions  would  be quite incorrect.  This  is  readily  apparent if one notes  that the  additional 
dose due to  Chernobyl is  only  a minor fraction of the natural radiation exposure and  that it  is 
also  small  compared  to  the  geographic  variations  of the  natural  radiation  background  which 
are  normally  disregarded,  and  are certainly  not seen  as  threats.  Any  quoted  number,  such  as 
the tentative figure  of 20  000  additional cancer deaths, would  have to be measured against the 
expected  number  of about  80  million  cancer deaths  to  occur  among  those  presently  alive  in 
the European community.  Prevailing cancer mortalities would,  therefore, be enhanced by  much 
less  than  one  part  in  a  thousand  and  - objectionable  as  such  an  increase  may  be - it  is  far 
below the threshold of statistical detectability and equally far  below the changes brought about 
by  other risk factors  that are voluntarily or unvoluntarily accepted. 
A  global  epidemiologic investigation  of possible  radiation  effects  after  the  Chernobyl  accident 
comprising all  countries,  and  all  cancers  in  the entire populations must clearly be rejected. The 
question  then  arises,  whether  there  are  specific  age  groups,  specific  cancers  and  specific 
geographical  regions  that  may  still  offer  possible  research  targets.  This  is  considered  in 
subsequent sections. 
- 23  -4.2  Childhood Cancer 
A critical age group with  high  radiation sensitivity are those who  were infants or were in  utero 
during  the  period  of enhanced  radiation  exposure,  i.e.  the  first  year  after  the  accident.  In 
epidemiological  studies  the  enhanced  prenatal  sensitivity  can  be  taken  into  account  by 
reference  to  the  dates  of birth  of affected  children,  and  not  to  the  date  of diagnosis  of a 
tumour.  The consideration of birth cohorts would  bring out more clearly any  transient peak in 
childhood tumour rates, if it occurred in  those prenatally exposed. 
According  to  the  statistical  analysis  of childhood  cancers  and  their  association  with  prenatal 
diagnostic  x-ray  exposures,  a  probability  of  0.1  per  Gy  to  develop  a  solid  tumour  or  a 
leukaemia  before  age  10  may  - as  has  been  pointed  out  (Sect.3.2.2)  - be  a  reasonable,  if 
conservative, estimate. 
Within  the European Community the most  highly  contaminated regions with  the highest  doses 
were  Northern  Italy,  Southern  Germany,  and  Greece.  Doses  between  1  mGy  and  3  mGy  for 
critical  groups  (e.g.  infants  and  children)  were  estimated  in  these  regions  for  the  first  year 
after the accident (Annex B). 
For all  prenatally exposed  during  this  period one estimates  a  collective  dose in  the  European 
Community of up  to  1 000  personGy due  to  the reactor accident;  this  includes  a  contribution 
of Italy  and  Germany each of 300  to 500  personGy.  For particular subgroups,  such  as  60  000 
infants  born  in  the  southeast  of Bavaria  in  1987,  an  increase  of childhood  cancer  of 9  cases 
within  the next  10 years  would  be assumed,  beyond  60  cases  expected  (background  rate). This 
number,  which  is  based  on  the  tentative  risk  factor  of 0.1/Gy,  would  correspond  to  an  excess 
relative  risk  of  about  15%  and  this  would  be  at  the  lower  limit  of  eventual  delectability 
(Annex  B,  Tab.B.3  and  Annex  D).  However,  one  must  note that the considerations  in  Annex 
D  are based on criteria for  a stationary and  uniform  population.  In reality one deals  also  with 
secular and  geographic variations of cancer rates which  would  obviate valid  conclusions  even if 
the theoretical conditions for  statistical discrimination were met. 
- 24  -The comparison between small  subpopulations  is  a central problem  in  epidemiological designs; 
one must  seek  the  most  suitable  balance  between  a  reduction  of group  size  towards  higher 
exposures  and  an  extension  of group  size  towards  larger  overall  numbers  of the  prenatally 
exposed.  The  power  of statistical  evaluations,  i.e.  the  probability  for  proving  enhancements, 
may be similar whether one examines a small subgroup with  higher exposure or a larger group 
with lower exposure. 
4.3  Cancer of the Thyroid 
The thyroid  was  a critical  organ  in  the initial  phase of the radioactive contamination after the 
reactor  accident.  Although  parents  have  largely  avoided  the  use  of fresh  milk  in  the  weeks 
after  the  accident,  there  appears  to  have  been  an  average  thyroid  dose  of 3  to  10  mGy  for 
children, and a thyroid  dose about 5 to 10  times smaller for  adults  (Tab.B.2). 
For  adults  it  is  certain  that  any  increase  of  thyroid  cancers  will  remain  undetectable.  A 
Swedish  study  of a  large  number  of patients  subjected  to  thyroid  doses  from  1-131  that  are 
several thousand  times  higher  than  those  due  to the Chernobyl  accident has  failed  to  indicate 
significantly enhanced rates of thyroid  cancers  after a mean period  of observation of about 25 
years. 
For children,  and  for  those  exposed  prenatally,  the question deserves  a  more detailed  analysis. 
In  the  study  of children  exposed  to  external  x-ray  exposure  for  ringworm  of  the  scalp  a 
marked  increase  of thyroid  cancers  has  been seen,  although  the estimated dose  to  the thyroid 
was  only  about  100  m  Gy.  For children with  a  thyroid  dose  of 3  to  10  m  Gy  after the reactor 
accident,  increased  thyroid  cancer  rates  might,  therefore,  not  be very  far  from  the  limits  of 
detectability.  However,  animal  studies  as  well  as  the Swedish  epidemiological studies  on 1-131 
patients  suggest  strongly  that  the  low  dose  rate  exposure  from  1-131  is  substantially  less 
effective per unit dose in  inducing thyroid  cancer than acute external x or gamma irradiation. 
- 25  -It would,  therefore,  seem  that  any  increased  rates  in  thyroid  cancer,  even  in  those  exposed 
prenatally or as  children, will  remain undetectable (Annex A,  {A13,  A14,  A26)). 
A  further  argument  against  epidemiological  studies  of  thyroid  cancer  after  the  Chernobyl 
accident  is  the  difficulty  in  diagnosis  and  the  resulting  incompleteness  and  uncertainty  of 
registry  data.  Finally,  one  must  consider  that  there  has  been  widespread  and  largely 
uncontrolled  administration  of stable  iodine  in  varying  doses;  this  could  change  substantially 
the  rates  of  non-malignant  alterations  in  the  thyroid.  There  is,  therefore,  no  possible 
justification  for  thyroid  studies  in  connection  with  the  reactor  accident  and  the  resulting 
radioactive contamination in  the European countries. 
4.4  Genetic Effects 
As  stated in Section 3.2.3,  the dose to double hereditary defects  (genetic effects) may be about 
1  Gy.  An  added  dose  in  the  order  of  1mGy  due  to  the  radioactive  contamination  from 
Chernobyl  could  then  increase  the  rate  of genetically  transmitted  disorders  by  about  0.1 %. 
Such  an  increase  need  not  be  unimportant,  but  it  would  be  far  below  the  threshold  of 
statistical detectability,  and it would  remain invisible,  even if the risk factor were far  higher. 
The period  after  the  reactor  accident  was  replete with  poorly supported  but  highly  publicised 
reports  of  hereditary  damages  and  of  prenatal  malformations.  All  these  reports  remained 
unsubstantiated, and some particularly sensational assertions were almost immediately traced to 
faulty  data collection or erroneous interpretations. An example was  the assumed  relation of an 
observed  Down's syndrome cluster  in  Berlin  to  a radioactive contamination which,  in  this  city, 
had  never  reached  radiation  levels  constantly  present  in  other parts  of the country.  An  even 
more glaring  misrepresentation was  a subsequent faulty  analysis  of data from  prenatal analyses 
performed  in  the  months  after  the  accident  within  the  Federal  Republic  of Germany.  Later 
coordinated studies with better methodology demonstrated no  irregularities. 
- 26  -The continuing study  of the children  of the  atomic  bomb  survivors  who  have  been subject  to 
much  higher  radiation  doses  has,  up  to  this  point,  demonstrated  no  increase  of hereditary 
damage;  it shows  the futility  of initiating a study that relates to doses of one or a few  mGy.  In 
subsequent sections  it will,  nevertheless,  be pointed out that there are valid  general reasons  to 
monitor  registries  of  hereditary  defects  for  known  and  unknown  factors.  Even  without  a 
decision  for  a  specific  radiation  study  there  can  thus  be  surveillance  of  the  frequency  of 
hereditary defects. 
4.5  Malformations 
There  is  no  evidence  that  prenatal  radiation  exposures  after  the  Chernobyl  accident  in  the 
countries  of  the  EC  have  caused  malformations.  Malformations  are  acute  effects  with 
substantial dose  thresholds;  they can be caused by  considerable injury to the developing foetus, 
and  by  radiation  doses  largely  in  excess  of 0.1  Gy.  With  the  possible  exception  of mental 
retardation,  all  malformations  would  require  far  higher  doses  than  those  caused  after  the 
reactor accident in  the European countries  and  any  increased  probabilities are projected  to  be 
far  below the level of statistical detectability. 
4.6  Mental Retardation 
There is  evident  need to  study possible  damage to the central nervous  system  of children who 
were  exposed  in  utero  among  the  population  around  Chernobyl  that  was  evacuated  after 
receiving  doses  of several  hundred  mGy.  However,  even  in  the  most  highly  contaminated 
countries of the European Community,  it  is  very  unlikely  that a  foetus  could  have  reached  an 
excess  dose  of 0.2  mGy  during  the  critical  period.  But  even  if  that  dose  had  been  reached, 
and  if the linear estimate of 0.4/Gy  were valid,  the number of mental retardations due to the 
exposure would  be less  than one case  in  10  000  newborn  exposed  in  the critical  foetal  phase 
which  is  substantially smaller than the prevalent occurrence of severe mental retardation which 
- 27  -is  in  the order of 0.002  (two  cases  in  1 000  newborn).  It is,  therefore,  highly  unlikely  that any 
increased frequency could be recognized statistically. 
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The feasibility  of epidemiological  investigations  depends  crucially  upon  the  existence  and  the 
reliable  continuity  of adequate registration  systems  for  health effects  that could  be caused  by 
ionizing  radiation.  The  availability  and  quality  of  registration  and  certification  systems  in 
different  countries  and  in  the  different  parts  of these  countries  must,  therefore,  be carefully 
examined. 
5.1  Data Collection and Registries 
Studies  of health effects  following  the  Chernobyl  accident  could,  in  principle,  be attempted in 
several ways: 
by  examination of routinely collected data to  monitor incidence trends and geographical 
variations or radiation induced diseases; 
by designed epidemiological studies based on existing and ongoing data collection; 
by  specifically  designed  studies  and  data  bases,  as  in  the  follow-up  of the  population 
evacuated from  the region around Chernobyl. 
To  study  time  trends  of disease  rates  and  to  detect  possible  changes  after  the  Chernobyl 
accident,  it  is  necessary  to  determine  reliable  baseline  rates  and  to  estimate  accurately  any 
existing trends before the accident. 
For  comparisons  of  rates  between  areas  with  different  contaminations,  it  is  important  to 
analyse  the collected  data with  comparable methods.  The two  types  of analysis,  the studies  of 
temporal  or  of geographic  variations,  can  be  combined  in  order  to  contrast  time  trends  in 
exposed  and  non-exposed  areas.  For  example,  one  might  compare  temporal  trends,  suitably 
- 29  -standardised for  demographic changes,  in  southern and  northern Germany,  or in  northern and 
southern Italy.  Most other countries of the EC incurred largely  uniform  contaminations so  that 
they invite no consideration of internal comparisons. 
A general criterion for  the feasibility  of studies  is  the presence or absence of data registries  in 
areas where the fall-out was  highest.  This  applies equally to designed studies. 
An  attempt  will  be  made  in  subsequent  sections  to  list  potential  sources  of  data  on 
malformations,  hereditary  and  carcinogenic  effects.  Such  sources  need  to  be  utilized  for  any 
survey  of  incidence  (or  prevalence)  rates  and  their  possible  changes  after  the  Chernobyl 
accident.  A  more detailed  review  of existing  registries  on birth defects  and  on cancers  is  given 
in Annex C.  It is  accompanied by  information on ongoing monitoring studies. 
5.1.1  Malformations and Genetic Effects 
Collecting  information  on  birth  defects  and  chromosomal  damage  (Annex  C)  has  long  been 
recognised  as  a  task  requiring  specialised  registries  and  trained  pediatricians  and  nurses.  It  is 
well  known  that  the  data  collected  on  birth  certificates  are  inadequate.  National,  sub- or 
supranational  registries  are,  therefore,  required,  and  such  registries  have  been set  up  in  most 
countries of the European Community. 
Most  of  the  registries  were  established  before  1980  and  can,  consequently,  provide 
pre-Chernobyl baseline prevalences of particular congenital anomalies calculated for,  at least,  5 
years.  The  fraction  of total  births  monitored  by  the  registries  in  each  particular  area  is  high 
(over  90% ),  and  the  possibility  of  a  bias  through  increased  reporting  after  Chernobyl  is 
correspondingly  small.  A  possible  bias  must  nevertheless  be  borne  in  mind.  The  registries 
which  indicate  100%  coverage  carry  out  periodic  checks  of  their  completeness  for  specific 
anomalies. 
- 30  -Two  different  types  of  damage  can  be  studied,  developmental  abnormalities  (such  as 
congenital  malformations)  and  genetic  disorders.  Their  time  patterns  are  different: 
developmental  abnormalities  would  appear  within  a  limited  period  corresponding  to  birth 
cohorts  which  were  prenatally  exposed  during  the  sensitive  embryo-foetal  period  (between  3 
and  16  weeks  after  conception,  i.e.  during  organogenesis);  genetic  abnormalities,  unlike 
developmental ones,  are often transmissible to subsequent generations. 
For  the  detection  of developmental  effects,  anomalies  of the  central  nervous  system  (Down's 
Syndrome,  Microcephaly,  severe  mental  defects  etc.)  are  of particular  interest  (cf.  Sect.3.1). 
The ability of monitoring systems  for  birth defects  to detect new  teratogenic risks  is  limited  by 
sample sizes  and  the magnitude of the relative  risk  (see Annex D  for  a discussion  of statistical 
power).  The populations which  were most  exposed  due to  the  Chernobyl  release  are only very 
incompletely monitored,  and  the very  small  frequency  of the expected  effects  make it virtually 
certain that any  teratogenic risk would  remain undetectable (Sect.3.1  and  4.5). 
A  joint  ad  hoc  evaluation  of the  frequency  of central  nervous  system  malformation  in  18 
regions  in  Europe  has  been  carried  out  by  a  working  group  of  the  EUROCAT  Central 
Registry  of Birth  Defects  for  the  period  since  the  reactor  accident.  It  shows  no  increases  in 
the  frequency  of  malformations.  The  six  classes  of  analysed  anomalies  were:  neural  tube 
defects,  arhinencephaly,  microcephaly  and  brain  reduction,  hydrocephaly,  anophthalmos  and 
microophthalmos, and congenital cataract (C5). 
Mutations  can  be  detected  at  the  chromosomal  or  at  the  gene  level.  If radiation  tends  to 
create chromosomal deletions,  translocations  and  inversions,  rather than non-disjunctions which 
have  been recorded  but are rare  (see Annex C),  it  would  be necessary  to  distinguish  between 
de novo  and inherited mutations,  the latter being in  the majority. 
At  the  gene  level,  sentinel  phenotypes  are  indicators  of germinal  dominant  gene  mutations. 
Sentinel  phenotypes  include  sentinel  abnormalities  which  are  recorded  in  congenital  anomaly 
registries,  with  an  expected  prevalence  rate  of 2.6  per  10  000  births.  A  study  of  sentinel 
- 31  -anomalies  would  require  specific  standardisation  throughout  the  registries  and  - with  few 
exceptions - it would  be difficult to assess  their prevalence retroactively. Although the expected 
effect  would  be cumulative,  and  although  it  might  be interesting  to  monitor  trends  over  the 
next  decade for  possible  increases  in  areas  with  highest  exposure,  one would  be very  unlikely 
to  detect  effects.  To  be detectable  they  would  require  doses  which  are  orders  of magnitude 
larger  than  those  produced  by  the  radioactive  contamination  in  the  European  countries 
(Sect.4.4). Such doses occurred only in  the near vicinity of the Chernobyl reactor. 
5.1.2  Cancers 
Tumour  rates  can  be monitored  either  in  terms  of incidence  or of mortality  data.  We  shall 
describe  here in  detail  data bases  for  measuring  cancer  incidence,  although  they  exist  only  in 
some specialized  registries,  while  age  and  site specific  mortality data are available nationally in 
all  countries of the EC. 
Analyses  of mortality  data would  be  appropriate with  regard  to  those  cancer  sites  for  which 
mortality is  nearly equal to  incidence  (e.g.  lung  or stomach).  For childhood  cancers  this  is  not 
the  case  and  the  situation  has  become  even  more  complicated  because  there  have  been 
important  advances  in  therapy,  so  that  mortality  rates  have  not  paralleled  incidence  rates  in 
recent  years.  Hence,  incidence  rates  for  childhood  cancer  may  have  stayed  substantially 
unchanged,  whereas  mortality  data  can  show  reductions  by  factors  up  to  3.  Delayed  cancer 
deaths may complicate the data further. 
For  thyroid  cancer  which  is  rarely  fatal  there  is  an  even  more  striking  lack  of connection 
between  incidence  and  mortality  data,  and  the  problem  is  further  complicated  by  the  poorly 
defined diagnosis of thyroid  cancers. 
Incidence  data  recorded  in  the  registries  are  subjected  to  a  variety  of checks  for  duplication, 
coding  errors,  and  for  completeness.  The  percentage  of histologically  confirmed  cases  is  high. 
Hence assessment errors are minor. 
- 32  -Information  on  confounding  variables,  such  as  new  health  screening  programmes  or 
reorganisations  of medical  services,  is  provided  by  the  registries.  Age,  sex,  place  of residence 
and detailed diagnoses are also  routinely recorded for  each case. 
For the comparison of incidence  rates  in  different areas numerous  etiological  factors  - genetic 
and  environmental  - need  to  be  taken  into  account.  There  are  also  some  specific 
characteristics  of the  registration  procedure  which  can  influence  the  comparability  of rates. 
These  may  differ,  depending  on  the  extent  of medical  facilities,  and  this  has  consequences 
both  for  the  accuracy  of diagnosis  and  the  completeness  of the  records.  For  all  registries  in 
the European Community the notification of cases  is  voluntary and  not compulsory by  law.  In 
addition,  variations  may  occur  due to  the systems  of codification  and  the checking  procedures 
for  misclassification. 
With  regard  to  adult  cancers,  any  effect  of the  Chernobyl  accident on time trends  would  not 
be expected for  at least some years;  the reason  is  that,  even for  leukaemias,  the latencies  are 
at  least  2  years  and  usually  considerably  longer.  Other  main  etiological  factors  of  adult 
cancers,  and  especially  leukaemias,  include  exposure  to  chemicals  (solvents,  pesticides  and 
insecticides,  antineoplastic  drugs),  and  the  time  variations  of such  factors  would  need  to  be 
assessed.  Hence it would  be difficult to distinguish  any effects due to the reactor accident from 
other fluctuations. 
In  view  of the  initial  high  contamination  with  1-131,  thyroid  cancer  is  a  concern.  However 
there  are  difficulties  in  the  registration  of thyroid  lesions,  and  latency  periods  are  long.  A 
study  of thyroid  effects  would,  therefore,  require  specially  designed  surveys  and  could  not  be 
achieved  through  incidence  registries.  The  Swedish  study  of  patients  who  had  been  given 
substantial  activities  of 1-131  for  diagnostic  and  therapeutic purposes  illustrates  the difficulties. 
In  spite  of far  higher  doses  and  an  average  observation  time  of 25  years  no  enhanced  rates 
have been found. 
- 33  -5.1.3  Childhood Cancers 
The  analysis  of time  trends  needs  to  be restricted  to  the  most  sensitive  sites  and  the  most 
sensitive  age  groups  for  radiation  induced  cancers.  These  are  primarily  childhood  leukaemias 
and,  more generally,  all  childhood cancers (Sect.4.2). 
A study of childhood  cancer based on the registries  listed  in  Annex  C,  Tab.C.4, would  include 
areas with  medium  to high  caesium  contamination (Southern Germany, Northern Italy,  Eastern 
France,  Scotland  and  Wales)  and  areas  of low  contamination  (Denmark,  The  Netherlands, 
Southern  England  and  Spain).  Shifts  in  the  time  trends  in  exposed  areas  could  thus  be 
com pared to any shifts  in  less  exposed  areas. 
All  the population registries  listed  in  Annex  C,  Tab.C.4,  with  two  exceptions,  were established 
at  least  five  years  before  Chernobyl  and  one  can  thus  assume  that  near  completeness  of 
registration  has  been  attained.  Clearly  the  longer  the  registry  has  been  operating,  the  less 
artefacts  will  occur  in  the incidence  data  and  their  time dependences.  Hence a  good  baseline 
estimation  for  areas  ranging  from  high  (Southern  Germany  and  Northern  Italy)  to  low 
exposure can be obtained.  For registries  covering  only  a small  population,  r~ndom fluctuations 
of a rare disease can be important and  can mask any  true changes of the mean frequencies. 
Presuming  a  roughly  similar  time  course  of all  childhood  cancers  one  could  pool  them,  to 
obtain  better statistical  resolution.  Among  the  more  highly  contaminated  regions  in  the EC -
such  as  Northern  Italy,  Greece,  or  Southern  Germany  - there  appears  to  exist  only  for 
Germany a childhood  cancer registry suitable for  the purposes which  have been outlined  here. 
This  registry  has  a  comprehensive data  base,  i.e.  it  contains  nearly  all  cases  (about 1 000  per 
year)  (Annex C,  Tab.  C.4). 
With  an observation period of about 10 years  and  with  the estimated excess  relative risks  (see 
Tab.B.3)  due  to  the  Chernobyl  accident  a  study  based  on  the total  population of children  in 
the Federal  Republic  of Germany  (6  million)  or  a  study  of a  regional  subpopulation  (60  000 
- 34  -II 
to  600  000)  could  conceivably  come  close  to establishing  an  effect with  statistical  significance 
(Annex  D).  Therefore,  childhood  cancer  appears  to  be  the only  post-Chernobyl  effect  which 
might under the tentative assumptions be detectable  . 
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Fig.  1 
Diagram of possible dependences of  the  increased  leukaemia mortality  on 
dose.  Data are from the atomic bomb  survivors  of  Hirosh~a and  Nagasaki 
(A20,  cf.  Fig.  A.2.)  for  doses between 0.1 Gy  and  3  Gy.  The  coefficient 
of variation  for  the plotted points  ranges  from  about  25%  to  50%.  The 
linear  extrapolation  (solid  line)  is  used  for  a  conservative  risk 
est~ate at  low  doses.  Radiobiological  studies  suggest  that  the  actual 
dependences  for  sparsely  ion1z1ng  radiations  are  linear-quadratic 
(broken line).  There is no  evidence for a  dose  dependence with threshold 
(dotted line). 
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 ANNEXES Annex A: 
Sources of Knowledge on Risk Factors for Radiation Induced Late Effects 
General remarks: 
Immediately  after  the discovery  of x-rays  in  1895,  there was  a  rapid  development  of medical 
applications,  but soon  there were  also  observations  of harmful  effects,  such  as  x-ray  induced 
skin  damage.  Only  a  few  years  later,  the first  skin  cancers were  observed,  and not much  later 
the first  leukaemias occurred in  radiologists. 
In  the  subsequent  decades,  tragic  experiences  resulted  from  the  uncontrolled  use  of 
radionuclides,  and  one  of the  most  serious  examples  is  the  fate  of the women  who  painted 
luminous  dials  with  radium-226  and  who  incorporated  large  amounts  of  this  long-lived 
alpha-emitter  when  they  tipped  the  paint  brushes  with  their  lips.  A  large  number  of bone 
cancers and other cancers occurred among these women. 
There  was  a  similar  lack  of radiation  protection  for  other  radium  workers,  and  there  was 
failure  to  understand  radiation  risks  when  an  alpha-emitting  contrast  medium,  thorotrast,  was 
widely  used  for  angiography  (the representation of blood vessels  in  x-ray  images).  There were 
also  instances  of medical  misuses,  such  as  the  injection  of high  activities  of the  short-lived 
radium-224  for  the  intended  treatment  of ankylosing  spondylitis  (a  degenerative  disease  of 
skeletal joints)  and  childhood  bone  tuberculosis.  And  there was,  to  name  a  further  example, 
inadequate radiation protection in  uranium  mines or in  other mines with  high  radon levels. 
The  resulting  tragic  experiences  affected  numerous  individuals,  but  they  have  also  become  a 
source  of knowledge  on  the  risks  for  radiation  carcinogenesis.  Further  important  information 
has  resulted  from  a  variety  of  diagnostic  or  therapy-related  applications  of  x-rays  or 
radionuclides in  medicine. 
- 43  -The most  important data on the late effects  of ionizing  radiations  have  been obtained during 
the last four decades from  the observation of the fate of the survivors  of the atomic bombings 
in  Hiroshima  and  Nagasaki.  Beyond  the enormous  extent  of destruction  and  the hundreds  of 
thousands of deaths,  immediately and  in  the days  and weeks  after the bombings,  the surviving 
population remained  subject  to increased  cancer rates  that were seen and  are still  being seen 
in  those exposed to higher doses. 
The  subsequent  paragraphs  contain  more  detailed  information  on  specific  sources  of 
knowledge on risk  factors  for  radiation induced late effects. 
Synopsis of data sources: 
Radiobiology  and  epidemiology  are  the  two  main  sources  of  knowledge  concerning 
radiation-induced  late  effects  and,  specifically,  radiation-induced  cancer.  Radiobiolo~ical 
experiments  at all  levels  from  molecular systems  to exposed  animals  are a basic but somewhat 
indirect source.  The studies  have  led  to important general conclusions  and  they have  provided 
guidelines  for  comparisons  and  for  extrapolations  of more  direct  data.  Actual  risk  estimates 
must,  however,  be based on epidemiological studies. 
Epidemiolo2ical  studies  are  the  major  source  of information  on risk  factors.  The information 
they  provide  is  also  indirect,  because it  is  based  on extrapolations from  high  doses  to  the low 
doses which  are encountered in  radiation protection. 
The  main  human  populations  which  have  been  exposed  and  were  later  subject  to  follow-up 
studies are listed below: 
Occupational exposure: 
- Dial painters who  ingested large amounts of radium-226 containing material 
- 44  -ll 
- Uranium miners who  were  exposed  to radon daughters,  i.e.  the  a-emitting decay products 
of radon, in underground mines 
- Workers in  nuclear industries who  were occupationally exposed to low dose-rate radiation 
Patients who were treated by  a variety of therapeutic medical procedures: 
X-ray  therapy of the 
- spine and  pelvis  in adults with ankylosing spondylitis 
- chest for  enlarged thymus  in infants 
- scalp  in  children with ringworm  (tinea capitis) 
- neck and head for various lymphatic abnormalities 
- skin  for  acne and hemangiomas 
- breast in  women with  postpartum mastitis 
Radium-224 therapy 
- for  tuberculosis  and ankylosing spondylitis 
Radioiodine therapy 
- for  ablation of the thyroid  gland 
Patients who were exposed due to  dia~nostic procedures: 
- fluoroscopy  for  pneumothorax in  women with tuberculosis 
- thorotrast injections 
- prenatal irradiation 
- radioiodine examination of the thyroid 
A-bomb  survivors  of Hiroshima  and  Nagasaki  who  represent  the  largest  and  most  important 
exposed human collective. 
The most relevant groups of these and related studies will  be briefly considered here. 
- 45  -Dial painters 
Between 1915  and  1930  hundreds  of young  women,  especially  in  the USA,  were  employed  to 
paint watch  and  instrument dials  with  fluorescent  material containing radium-226.  Pointing the 
brushes  with  their  lips  they  incorporated  very  large  amounts  of the  long-lived,  a -emitting 
radium-226.  Later,  they developed  grave  radiation effects;  many of these women died  of bone 
sarcomas,  or cancers  of the mastoids  and  nasal  sinuses.  The doses  were very  high  and various 
acute radiation damage has  been described in  the dial  painters. A follow-up  study published  in 
1986  (1)  covers  a  period of more than 50 years.  It includes  about 2 000  US  dial  painters with 
known  radium  body contents.  Out of these,  about 500  had  died  up  to  that date,  among them 
there were 60  deaths from  bone sarcoma, sinus or mastoid carcinoma. 
The  dial  painters  represent  the  radiation-exposed  group  with  the  longest  observation  period; 
however,  the data are of limited value for  risk  estimation. This  is  so  because the exposure was 
due to densely ionizing  radiation and because  high  activities  were distributed  inhomogeneously 
within  the  body.  It was,  therefore,  difficult  to  obtain  reliable  dose  or  organ-dose  estimates, 
and,  more importantly, there was  no adequate follow-up  study, while most of the exposed were 
still  alive.  The  probability  that  bone  tumours  or  other  radiation-induced  malignancies  were 
reported  may  have  depended  on  the  cumulative  dose  because  the  extent  of  damage 
determined  the  degree  of medical  supervision.  The  dose-response  relationships  inferred  from 
these data are,  therefore, somewhat uncertain. 
Occupational exposure of nuclear industry workers 
The lasting debates on cancer risks  associated with  exposures  to  low  doses  and  low  dose rates 
has  prompted a  number of studies of cancer incidence and  mortality in workers  in  the nuclear 
industry.  Together,  these  studies  cover  nearly  120  000  employees  with  a  mean  follow-up  of 
about 20  years,  mainly in  the UK and  the USA (2,  3,  4,  5).  Generally the mortality rates from 
cancer  and  other  causes  of death  in  these  study  populations  were  below  national  average 
rates.  No  excess  deaths  from  malignant  diseases  were  revealed  in  comparison  to  the  general 
- 46  -population.  The low  mortality  rates  are,  at least  partly,  explained  by  the  selection  of healthy 
employees,  by  above  average  health  care,  and  by  other differences  from  a  normal  population 
in  medical care and supervision, social conditions, social services  and related factors. 
For  leukaemias  the  situation  is  more  complex.  Most  studies  do  not  reveal  an  increase  of 
leukaemia  rates,  but some of the studies would  appear by  themselves  to  indicate increases  (2, 
4).  None, however,  attain statistical significance. 
The total  number of observed  employees  is  high  (and  comparable to  the number of A-bomb 
survivors).  However,  the number of deaths is  small  (5  to 15%  in different studies);  this  reflects 
the  age  structure  of these  young  working  populations.  The  dose  levels  are  also  lower  than 
those  of the A-bomb  survivor  population.  Both  factors  account  for  the fact  that none of the 
studies  of  workers  has  yet  provided  actual  numerical  risk  estimates,  and  it  is,  therefore, 
apparent that the studies of workers  need to be continued. 
A  variety  of partly  contradictory  studies  on  cancer  risk  due  to  occupational  exposure  have 
generated  much  controversy  with  respect  to  dose-effect  relations,  statistical  procedures,  risk 
estimates, etc. 
It  is  beyond  the  scope  of this  document  to  review  in  detail  the  existing  publications  on  this 
topic  or to  give  a  resume  of their  quality  or validity.  Some,  but not  all,  of the discrepancies 
between  the  investigations  appear to  vanish  as  more  information  accumulates.  However,  even 
in  their  entirety,  the  worker  data  cannot  provide  actual  risk  estimates.  They  can  merely 
determine  ranges  of possible  values,  and  these  ranges  are  equally  consistent  with  no  effects 
and  with  risks  substantially  larger  than  the  estimates  considered  in  this  document.  The 
epidemiological  studies  on  nuclear  industry  workers  are,  therefore,  not  directly  relevant  as 
sources  of risk  estimates  for  the present study.  However,  they  are clearly  relevant with  regard 
to  their  methodological  aspects.  Any  epidemiological investigation  at low  doses  would  need  to 
utilize the methods that have been developed in  these studies. 
- 47  -X-ray therapy for ankylosing spondylitis 
In Britain, during the period from  1935  to 1955  a commonly utilized  treatment of patients with 
ankylosing  spondylitis  was  x-irradiation  (in  several  courses)  to  the  spine  and  pelvis.  The 
patients  reported  substantial  pain  mitigation  or  even  improvements  of  their  condition. 
Subsequently,  however,  it  appeared  that  the  treatment  led  to  an  increased  risk  of cancers, 
especially of leukaemia.  A  subsequent extensive  epidemiologic  investigation,  published  in  1957 
(6),  included  more  than  13  000  patients  with  doses  to  the  spinal  marrow  of about  5Gy  per 
irradiation course.  At the end of the total follow-up  in  1970  (7,  8),  more than 14 000  patients 
were  included;  of these,  about  6000  with  an  average  follow-up  of 16  years  and  only  a  single 
course of treatment were selected for  further evaluations. 
The  principal  malignancies  for  which  quantitative  risk  estimates  could  be  obtained  were 
leukaemias.  The overall  observed/expected  case  ratio was  about 5.  After a  latency of about 2 
years,  the  rate  reached  a  maximum  at 3  to  5  years  after  irradiation;  subsequently,  about  20 
years  after the treatment, it declined  toward  the control levels.  A similar time course was  seen 
in  the A-bomb survivors  (see below). 
The marrow doses  ranged from  0.5  to 7 Gy  with  a mean of about 2.5  Gy  and a  risk  factor  of 
about  0.01/Gy  was  estimated.  The  risk  estimates  for  solid  cancers  are  in  general  agreement, 
although  somewhat  smaller,  than  those  derived  from  the  data  on  the  atomic  bomb  survivors 
(7,  8,  9). 
X-ray exposures of children with tinea capitis 
Between 1948  and 1960 children were irradiated in  Israel with x-rays  for  ringworm  of the scalp 
(tinea  capitis).  The  treatments  were  applied  to  the  head,  specifically  the  scalp.  The  final 
cohort  study  (published  in  1984)  (10)  included  more  than  10  000  persons  with  an  average 
follow-up  of about  20  years.  An  estimated  mean  dose  to  the  thyroid  of 100  mGy  led  to  a 
five-fold  increase  in  malignant  thyroid  tumours.  The  absolute  risk  factor  for  thyroid  cancer 
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incidence due to irradiation in childhood was  estimated to be about 0.03/Gy.  Since only one in 
ten  cases  is  lethal,  this  corresponds  to  a  mortality  risk  factor  of 0.003/Gy.  Children  of age 
between 0 and 5 years appear to be about 1.5  times more sensitive than older ones  (9,  10). 
Radium-224 therapy 
In  the  years  after  World  War  II  high  activities  of the  short  lived  a -emitting  radioisotope 
radium-224  were  injected  for  the  intended  treatment  of ankylosilig  spondylitis  and  of bone 
tuberculosis  in  children  and  adults  in  a  German clinic.  This  treatment has  given  rise  to  bone 
sarcomas,  and  to  various  noncancerous  lesions.  In  1952  a  follow-up  study  of  the  German 
radium-224  patients  was  begun.  The study  population contained  899  children  and  adults  who 
received  intravenous  injections  of radium-224,  resulting  in  skeletal  doses  from  0.05  to  50  Gy 
(11,  12).  Bone sarcomas were reported in 53  patients (compared to only 0.2  cases  expected on 
the basis  of population  statistics).  All  of these  bone  cancers  must,  therefore,  be  regarded  as 
radiation  induced.  A  detailed  statistical  analysis  revealed  a  linear-quadratic  dose  dependence 
which  did  not  appear  to  vary  with  age  at  exposure  or  sex.  In  contrast  to  most  other  solid 
tumours,  the  excess  risk  for  bone  sarcomas  does  not  run  parallel  to  the  age-specific 
spontaneous  rates.  Instead,  the  absolute  risk  model  is  applicable,  and  the  course  of  the 
bone-sarcoma  rate  can  be  approximated  by  a  temporal  wave  similar  to  that  observed  with 
leukaemias.  After a  latency of 2  to  4 years,  there  is  a  maximum  osteosarcoma  rate:  at about 
10  years  the  rates  begin  to  decline,  and,  after  20  to  30  years,  the  increment  has  virtually 
disappeared. 
The derived  lifetime  risk  factor  for  bone sarcoma  is  of the order of 0.01/Gy  of  a-rays  (12); 
this  result cannot, however,  be linked  to the possible effect of gamma rays. 
Iodine-131  in nuclear medicine 
For diagnosis  of thyroid  diseases  large  numbers  of patients  were  given  iodine-131  during  the 
period of 1951  and 1969.  A Swedish follow-up  study (the most recent results were published  in 
- 49  -1988  and  1989  (13,  14)),  covers  over 35000  persons who  were  followed  for  an average  period 
of 20  years  after administration of the  radionuclide.  The population-average dose was  0.5  Gy. 
The study  has  not revealed significantly increased  thyroid  cancer rates among the patients who 
received  diagnostic applications of 1-131.  However,  there has  been no fully  comparable control 
group  in  this  study,  and  it  is,  furthermore,  possible  that  the  diagnostic  procedure  had  some 
screening effect on thyroid cancers which would  otherwise have been found  later. 
Thorotrast injections 
The  x-ray  contrast  medium  Thorotrast,  an  a -emitting  thorium-232  dioxide  preparation,  was 
introduced  for  angiography  in  1929  and  - in  spite  of published  warnings  - it  was  used  until 
about  1950.  Its  application  has  caused,  apart  from  a  variety  of noncancerous  effects,  various 
tumours,  predominantly liver  tumours.  The major investigation is  the German Thorotrast study; 
it  started in  1967  and  it has  now  reached a total follow-up  of about 45  years  (15).  From  more 
than 5000  patients initially  recorded  about 2 000  were selected for  further  investigations.  18% 
of these  developed  liver  cancer,  compared  to  only  0.14%  expected.  The mean  liver  dose  rate 
due to Thorotrast injection was  estimated  to  about 0.02  Gy  of  a -rays  per year for  the typical 
injected  amount of the order of 40  mi. 
Similar  but  somewhat  less  extensive  studies  have  been  performed  in  Denmark,  Portugal  and 
Japan, however,  their results are less  fully  documented. 
Prenatal exposures from x-ray examinations during pregnancy 
Extended  case-control  investigations  of childhood  cancer deaths,  conducted  in  Britain  between 
1953  and  1979  revealed  a marked correlation of childhood cancer and  prenatal x-ray  exposure 
(16,  17).  Analyses  based on data from  the 'Oxford Survey of Childhood  Cancer'  include nearly 
15  000  geographically-matched  and  birth-date-matched  case-control  pairs.  They  represent  the 
largest  studies  of  prenatal  x-ray  exposure  and  childhood  cancer.  In  these  studies  it  was 
concluded  that about 7 to 8%  of all  childhood  cancers were caused  by  x-ray  examinations.  For 
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children  with  cancer who  had  been  diagnostically  exposed  in  utero,  an  attributability  of 50% 
was  inferred,  and  a risk  factor for  fatal childhood cancer of about 0.2/Gy has been stated. 
A similar result comes from  a case-control study in  32000  twins  born in  Connecticut from  1930 
to  1969;  among these 31  cases  of cancer were identified  (18).  Twins  who  developed  leukaemia 
or other childhood  cancer were  twice  as  likely  to  have  been exposed  to  x-rays  in  utero  than 
twins  who  were  free  of disease.  The derived  relative  risks  of 1.6  and  3.2  for  leukaemia  and 
other  cancers,  respectively,  at  average  x-ray  doses  of 10  mGy  correspond  to  risk  factors  of 
0.03/Gy  for  leukaemia  and  0.2/Gy  for  other cancers.  As  noted earlier,  such  high  risk  estimates 
do  not fit  the data from  Hiroshima and  Nagasaki. 
Follow-up of the atomic-bomb survivors 
Observations  of  the  fate  of  the  survivors  from  Hiroshima  and  Nagasaki  have  lasted  four 
decades  and  they  will  need  to  be continued  for  several  more decades.  Essential  findings  have 
been  published  in  a  series  of  recent  documents  from  the  Radiation  Effects  Research 
Foundation (RERF) (e.g.,  19,  20,  21,  22). 
Risk  estimates  by  the  United  Nations  Scientific  Committee  on  the  Effects  of  Atomic 
Radiations  (UNSCEAR) and  the International Commission  for  Radiological  Protection (ICRP) 
were  based  on data  up  to  the year  1975  and  on  a  dosimetry  for  the  atomic  bombs  survivors 
that was  subsequently recognized  to  be faulty.  The old  dosimetry  implied  that a  substantial,  if 
not the major,  part of the radiation induced  cancers  in  Hiroshima was  due to densely  ionizing 
neutron  radiation,  while  neutrons  played  no  major  role  in  Nagasaki.  This  appeared  to  be 
consistent with  an apparently linear dose  dependence for  leukaemias,  for  all  cancers,  and  also 
for  chromosome  aberrations  in  Hiroshima,  and  with  threshold-like  dose-response  relationships 
in  Nagasaki.  It was  thought  that at  low  doses  the  densely  ionizing  radiation  remains  effective, 
while  the  effectiveness  of the  sparsely  ionizing  gamma  radiation  is  considerably  reduced.  In 
line  with  this  assumption,  risk  estimates  were  obtained  which  included,  for  gamma  rays,  the 
assumption of a substantial reduction factor for  the extrapolation from  high to  low  doses. 
- 51  -The inferred  risk  factor  for  cancer mortality averaged  over all  ages  in  the exposed  population 
was  0.01  to 0.02  per Gy  (Tab.1,  main text).  For leukaemia the risk estimate was  0.002  to 0.004 
per Gy  (23,  24). 
The  revision  of  the  dosimetry  was  necessitated  by  the  conclusion  that  the  dosimetric 
computations for  neutrons were erroneous.  A  re-analysis,  performed  under broad international 
cooperation, has shown that the contribution of the neutrons to the total dose was  minor, even 
in  Hiroshima.  This  would  seem  to  lead  to  increased  risk  estimates,  since  a  substantial part of 
the effects  in  Hiroshima was  formerly  ascribed  to  neutrons but would  now  be assigned  to  the 
gamma  rays.  The  actual  analysis  showed  that  the  effects  of the  change  in  dosimetry  are  less 
marked  than one would  expect  (20,  21,  22),  because the revision  of the dosimetry  has  led  to 
higher  estimated  gamma-ray  doses,  particularly  in  the  range  of  low  doses.  A  number  of 
further,  largely compensating changes had  the overall effect that one obtains virtually the same 
excess-risk estimates for solid  cancers at doses  of one or several  Gy,  regardless of whether one 
employs  the  old  or  the  new  dosimetry  system  (Tab.A1).  For  leukaemias  the  situation  is 
different, and there is  an approximately 50%  increase of the risk  estimates due to the changed 
dosimetry;  the  technical  reason  is  related  to  the  fact  that  the  bone marrow,  as  an  organ  at 
fairly  shallow  depth,  is  differently  affected  by  changes  in  gamma-ray  penetration  through  the 
body than other, deep-lying organs. 
In spite of the lack,  or the small  magnitude,  of changes due to  the revised  dosimetry,  there is 
now  a  substantial  increase  in  the  risk  estimate  for  cancer  mortality  which  may  altogether 
amount  to  a  factor  up  to  10  (Tab.A1).  There  are  a  number  of reasons.  One  of the  most 
important  aspects  is  that  there  is  now  less  evidence  of a  decreased  slope  of the  dose-effect 
relation  at low  doses.  Since  the seemingly  linear  relationship  in  Hiroshima cannot be ascribed 
to  neutrons,  there is  less  justification for  employing  a dose-reduction factor  for  gamma rays  as 
it  was  introduced  by  UNSCEAR  and  employed  by  ICRP  (23),  to  account  for  an  assumed 
smaller  effect  at  lower  doses  and  lower  dose  rates.  In  the  most  recent  assessment  of 
UNSCEAR  (9)  possible  dose  reduction  factors  between  2  and  10  were  suggested,  but  these 
tentative  values  were  based  on  general  conclusions  of  radiobiology,  not  on  direct 
- 52  -epidemiological  evidence.  The recent studies  from  RERF (20,  21,  22)  have,  therefore,  quoted 
risk estimates without this  factor. 
A further reason for  increased  risk  estimates  is  the continuation of the observations since  1975 
which  have  in  almost  all  age  cohorts  shown  a  persistence  of the  increased  relative  risks  for 
solid  tumours.  This  has  increased  the  absolute  number  of cancer  deaths  approximately  by  a 
factor  of 2  at a  specified  dose,  and  a  further  increase  of about  a  factor  2  has  resulted  from 
the hypothetical lifetime projection of risk,  based on the relative  risk  model for  those who  are 
still  alive  (Tab.A1  ). 
Generally  it  was  concluded  that  the  data  for  solid  tumours  follow  the  relative  risk  model.  In 
this  model  irradiation  causes,  as  stated,  an  increase  of tumour  rates  that  begins  five  to  ten 
years  after  exposure.  The  increases  are  taken  to  persist  and  to  remain  proportional  to  the 
age-specific  rates.  The  proportionality  factors  depend  on  dose  and  also  on  age  at exposure. 
They tend to be higher for  those exposed  at younger ages. 
Contrary  to  observations  on  the  UK  ankylosing  spondylitis  patients  (7,  8),  and  also  to 
observations  on the uranium  miners,  there has  been no  indication  of decreasing  relative  risks 
several  decades  after  the  exposure  for  the  survivors  of the  atomic  bombings.  Accordingly, 
Preston  and  Pierce  (20)  have,  in  a  recent  analysis  after  the  dosimetry  revision,  derived  risk 
estimates which  are based on extrapolations throughout life. 
Fig.A1  compares  the ICRP  risk  estimate  (lower  broken  line)  from  data  up  to  1975  with  the 
most  recent  risk  estimate  (upper  broken  line)  that  is  based  on  the  new  dosimetry  and  on 
observations  until  1985.  The  latter relationship  is  primarily  related  to  the  left  ordinate which 
gives  relative  risk  factors  and  it  corresponds  to  the  initial  slope  of  the  explicit  dose 
dependence that is  given  as  a solid  line.  The data represent all  nonleukaemia tumours  and  all 
age  cohorts  combined.  Assuming  a  total  lifetime  cancer  mortality  of 20%,  one  deduces  the 
absolute lifetime  risk estimates  that are provided  on the right  ordinate. The direct comparison 
of the earlier estimates with  the more recent analysis  suggests  an increase in  risk  estimates by 
- 53  -a  factor  of up  to  10.  This  difference  is  the  product  of the  previously  mentioned  individual 
factors,  for which  rough values are listed  in  Tab.Al. 
For leukaemias  there has  been a  somewhat smaller change in  risk  factors,  because there have 
been  few  excess  cases  s1nce  1975;  the  waves  of  radiation  induced  cases  had  largely 
disappeared  even  before  1975.  The  continued  observation  has,  therefore,  not  contributed  to 
increased  risk  estimates.  Since  there is  no  need  for  further  projection  of risks,  the  estimates 
are more certain, except for  the question of whether a dose reduction factor applies.  However, 
as  stated,  there has  been an increase  by  about a  factor  of 1.5  due  to  the dosimetry  revision. 
Together with  an abandonment of the  dose-reduction  factor,  this  leads  to  an  increase  of the 
risk  estimates  by  a  factor  of  about  5.  Fig.A.2  compares  the  earlier  ICRP-estimates  for 
leukaemia with the new results. 
Figs.A1  and  A.2  are  accompanied  by  tables  of scaling  factors  for  three  age  groups  and  the 
two  sexes.  Applying  these  scaling  factors,  one  obtains  in  Tab.A2  the  values  of  new  risk 
estimates without assumed  reduction factors  for  low doses and low dose rates. 
In summary,  there is  only a minor increase of the risk estimates due to the changed dosimetry. 
The  major  change  is  an  indirect  consequence  of  the  revised  dosimetry  system;  the 
abandonment of an assumed  reduction factor for low  doses  reflects  the disappearance of direct 
evidence  for  a  nonlinear  dose  dependence;  for  both  cities  the  data  are  now  consistent  with 
proportionality to dose.  A further change is  due to  the extension of the observations to include 
not only  tumours  that have  occurred  since  1975  but also  those  that are projected  to occur  in 
the future,  i.e.  more than four  decades after the exposure in  the ageing cohorts. The mounting 
evidence of enhanced sensitivity of those exposed at younger ages  is  also  of importance, but it 
will  be several  more decades  until  definitive  data  are  available  about the  frequency  at higher 
ages of solid  tumours in  those who were exposed as  children. 
Hereditary  disorders  in  the  children  of  the  exposed  atomic  bomb  survivors  have  been 
intensively  studied  and  will  continue  to  be  studied,  but  no  statistically  significant  increases 
- 54  -have,  as  yet,  been identified.  Surveys  of other groups of radiation-exposed  persons,  too,  led  to 
the conclusion  that the association between radiation and hereditary damage is  too weak to  be 
statistically ascertained. The statistical uncertainty of the data is,  however,  sufficiently large that 
there is  no inconsistency with  risk  factors  deduced from  radiation studies with  mice.  From  such 
experiments  one estimates  that  hereditary  disorders  are  doubled  by  doses  of 0.5  to  2Gy  (9). 
With  a spontaneous  rate for  naturally occurring  hereditary effects of a  few  per cent,  a genetic 
risk  factor  of about  0.01/Gy  would  be  estimated.  Substantially  higher  risk  factors  would  be 
inconsistent  with  the  absence  of significant  increases  of hereditary  defects  in  Hiroshima  and 
Nagasaki. 
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Fig.A.l  Dose  dependence  of  the relative and  the absolute risk of 
cancer  mortality for  a  population of all ages  according 
to the results of  RERF  (20,  21).  The  upper dashed  line 
represents  the excess  lifetime risk.  For comparison  the 
risk estimations of  ICRP  (23)  with  and without  a  reduc-
tion  factor are indicated.  The  results of  the new ana-
lyses  refer to the study population of all atomic  bomb 
survivors. 
The  table below contains  the adjustment factors  for dif-
ferent  age  groups.  The  ICRP  estimates were  based  on data 
up  to  1975  and  relate to an  adult  working-age  popu-
lation. 
Age  at  Radiation  Exposure  <  20  20-35  >  35 
Females  2. 16  , • 29  0.71 
Males  0.97  0.58  0.32 
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Fig.A.2  Dose  dependence  of  the absolute risk of  leukaemia morta-
lity according to the results of  RERF  (20,  21)  under  the 
assumption  of  a  mean  time at risk of  32  years.  The 
dashed  line represent the mean  lifetime risk.  For  com-
parison the risk estimates  of  ICRP  (23)  with  and without 
a  reduction factor are indicated.  The  results of  the  new 
analyses  refer  to  the collective of all  atomic  bomb 
survivors.  The  table contains  the  adjustment  factors  for 
different age  groups.  The  ICRP  estimates were  based  on 
data  up  to  1975  and  relate to  an  adult  working-age 
population. 
Age  at  Radiation  Exposure  <  20  20-35  >  35 
Females  0.57  0.63  0.88 
Males  1 . 01  1. 46  1. 45 
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Factors  between  the  old  and  the  new  risk  estimates. 
Leukaemia  So 1 i d  tumors 
- Change  in  dosimetry  1  0  5  1.0 
- Inclusion  of  younger  cohorts  1.2  2.0 
- Extrapolation  throughout  life  1.0  2.0 
(depending  on  age  of  cohort) 
- Omission  of  a  reduction  factor  for  2.5  2.5 
small  doses  and  sma 11  dose  rates 
Resulting  total  factor:  4  .  . .  5  10.0 
Tab.A.l  Factors  of  increase  from  the previous  risk estimates  of 
ICRP26  (23)  for  a  working-age  population  to  the  risk 
estimates  for  an  age-averaged population considered in the 
present study. 
- 61  -NEW  DATA 
Age  at  Exposure 
<  20 
20  to  35 
>  35 
Average  over 
A·ge  and  Sex 
BEIR  III  (24) 
ICRP26  (23) 
F:  Females 
M:  Males 
Additional  Risk  per  Gray 
So 1  id  Cancers  leukaemia 
relative  absolute  absolute 
risk  excess-life- risk 
time  risk 
F  M  F  M  F  M 
1.08  0.49  0.19  0. 11  0.006  0.01 
0.65  0.29  0.12  0.07  0.006  0.014 
0.36  0.16  0.06  0.03  0.009  0.015 
0.5  0. 1  0. 1 
0.1  0.02  0.004 
0.05  0.01  0.002 
Tab.A.2  Estimated risk factors  for radiation-induced cancer 
mortality.  The  estimates  of  BEIR  refer to higher doses; 
the estimates of  ICRP  refer to the age distribution of 
an adult population.  The  new data are based on  recent 
results  from  RERF  (20,  21). 
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Annex B: 
Exposures to Radiation from  Chemobyl 
An unexpected  feature  of the release of radioactive  material  from  the  Chernobyl  reactor was 
not  only  its  magnitude  but also  the subsequent widespread  distribution  throughout  almost  all 
parts of the northern hemisphere,  and mainly across  Europe. The patterns of deposition varied 
according  to  the meteorological conditions  and wind  regimes  during the period of release.  The 
radioactive cloud  contained numerous different fission  products and  actinides  and,  traces  of all 
of  them  were  detected  in  most  countries,  but  only  comparatively  few  nuclides  were  of 
radiological  concern.  The  three  most  relevant  radioisotopes  were  1-131  and  the  two  caesium 
isotopes,  Cs  134 and Cs  137. 
After  the  accident  had  become  known,  most  countries  started  or  extended  monitoring 
programmes  for  radioactive  contamination.  The  data  have  been  utilized  by  a  number  of 
national  and  international  committees,  to  carry  out  assessments  of the  radiological  impact  of 
the  contamination.  The  data  reported  in  this  document  are  based  mainly  on  reports  by  the 
Organisation  for  Economic  Co-operation  and  Development  (OECD)  (1),  by  a  task  group  of 
the  British  National  Radiological  Protection  Board  (NRPB)  for  the  Commission  of  the 
European Community (CEC)  (2),  by  the German Bundesgesundheitsamt (BGA) for  the World 
Health  Organisation  (WHO)  (3),  and  by  the  United  Nations  Scientific  Committee  on  the 
Effects  of  Atomic  Radiation  (UNSCEAR)  (5).  They  summarize  rough  estimates  of 
contamination levels  and avera2e doses  in  member states of the European Community. 
Fig.B.1  gives  the measured  cumulative  1-131  and  Cs-137  depositions  in  Europe (3).  The levels 
of contamination  vary  widely  and  cover  ranges  from  hardly  detectable  to  several  hundreds  of 
kBq/m2• 
The  main  pathways  of  exposure  have  been  direct  gamma-irradiation  from  the  radioactive 
cloud,  inhalation  of activity  in  the  cloud,  gamma  irradiation  from  activity  deposited  on  the 
- 63  -ground,  and irradiation from  ingestion  of contaminated food.  The conversion from  the specific 
activity  in  the  atmosphere  in  Bq/m3  (inhalation),  the  deposition  on  the  ground  in  Bq/m2 
(external  exposure),  or  the  concentration  in  food  in  Bq!kg  (ingestion)  to  organ  doses  or  to 
whole-body  doses  is  performed  through dose  conversion  factors,  and  these are specific  for  the 
nuclides,  for  the geometries  of distribution,  for  the  biological  half lives  and  for  a  number of 
other parameters.  The determination of the conversion  factors  is  not a  topic of this  report;  it 
is  dealt with elsewhere (e.g.  (3)). 
Ingestion  (resulting  in  internal  exposure)  and  external  gamma  irradiation  from  deposited 
material (resulting in external exposure) were the dominant pathways.  The relative contribution 
of  these  two  pathways  to  the  total  exposure  varied  considerably  between  the  different 
countries.  The  overall  average  of the  dose  in  the  first  year  among  the  population  of the 
member states of the European Community was  about 0.2  mGy which  resulted  in  a  collective 
dose of about 60  000  personGy (EC population 320  million). 
The reports  from  OECD and  NRPB  include certain peak doses which  have been estimated in 
the  various  countries.  The  corresponding  subpopulations  in  the  higher  contaminated  regions 
(termed  critical  ~roups) would  be the  likely  target  collectives  for  conceivable  epidemiological 
investigations. 
Fig.B.2  shows  the  distribution  of average  doses  in  the  first  year  after  the  accident  in  some 
countries  of the European Community.  As  indicated  in  the insets  of the figure,  values  for  the 
entire populations are given  in  terms of the external,  internal,  and total dose for  children,  and 
for  critical  groups  (these groups  being  partly identical).  The most  highly  contaminated  regions 
with  maximal  doses  are  Northern  Italy,  Austria,  Southern  Germany,  and  Greece.  In  these 
countries  average  doses  between  0.5  mGy  and  1 mGy  have  been estimated  for  adults,  and  1 
m  Gy  to 3 m  Gy  for  critical groups. 
Tab.B.1  gives  the dose  estimates  from  OECD,  NRPB,  BGA,  and  UNSCEAR in  more  detail. 
The doses  are given  in  terms of whole-body doses  that are predominantly due to external and 
- 64  -internal  caesium  exposure.  The  values  in  Fig.B.2  are  rough  averages  of  the  estimates  in 
Tab.B.l. 
When different  radionuclides  are incorporated  they are distributed between the various  organs 
according  to  their chemical  properties. Thus,  there can be widely  different radiation exposures 
to  different  organs  by  different  nuclides;  but,  in  principle,  the  doses  to  each  organ  can  be 
computed or at least estimated in  terms of average metabolic parameters. 
Organ doses,  with  the exception of those for  the thyroid,  need not be considered separately in 
this  document.  The  bone  marrow  dose  (relevant  for  leukaemia  risk  estimation)  can  for  the 
present purpose be set equal to the whole-body dose by caesium. 
Because  of the initial  predominance  of iodine-131  in  the contamination  and  its  concentration 
in  the thyroid  gland after intake, thyroid  doses  have been evaluated separately. 
The  thyroid  doses  were  mainly  due  to  ingestion  (internal  exposure)  and  have  been 
accumulated within  a few  weeks  after the accident.  Comparing these doses  to  the thyroid with 
the whole body exposures due to  caesium  one concludes  that they may contribute about 10% 
of the total cancer risk due to the radioactive contamination. 
The  total  collective  thyroid  dose  to  the  EC  population  is  estimated  to  be  about  200  000 
personGy  (2/3  being contributed  by  Italy and  Germany).  The average  adult and  infant thyroid 
doses  in  the first  year are given  in  Tab.B.2.  In  adults  the highest  average doses  were  received 
in  Greece,  Italy  and  the  Federal  Republic  of  Germany  (several  mGy).  Infants  can  have 
received  doses  up  to  several  10  mGy.  The  contribution  of the  most  exposed  subpopulations 
(about  1%  of the  EC populations)  in  North  Italy  and  South  Germany  to  the  total  collective 
thyroid  dose may be about 10%  (i.e.  20  000  personGy  ). 
The  estimates  from  OECD,  NRPB,  BGA,  and  UNSCEAR  show  some  deviations  but  agree 
qualitatively  in  the most  relevant aspects.  OECD gives  the  highest  individual  whole-body  dose 
- 65  -of 2.9  mGy  for  a critical group  in  North Italy.  This  group,  however,  remains  hypothetical and, 
accordingly,  neither  the  size  nor  the  collective  dose  of this  group  is  stated.  For  the  total 
population of Italy  the collective  dose  is  estimated  to  about  25  000  personGy and  for  infants 
(first year of life)  about 350  personGy. 
Collective  doses  similar  to those  in  Italy occurred  in  the Federal  Republic of Germany  (total: 
about 20 000  personGy;  infants:  about 300  to 400  personGy), whereas for  most other countries 
the  collective  doses  are  substantially  less,  namely  of  the  order  of  100  personGy  and  less. 
Critical groups may be infants or foetuses exposed  in  utero;  they have enhanced sensitivity and 
have,  partly,  also  incurred  increased  doses.  Childhood  cancer  is  considered  as  the  most 
sensitive  indicator,  and  one  could,  therefore,  make  use  of childhood  tumour  registries,  and 
particularly the well  established one in  Germany (see Sect.5.1.3  and Annex C). 
An  adequate  choice  of regions  with  high  contamination  and  high  average  doses  could  yield 
values  of up  to  1.5  mGy  for  infants  in  the southeastern parts of Bavaria.  Tab.B.3  summarizes 
the  most  relevant  data  for  subpopulations  and  subregions  of  the  Federal  Republic  of 
Germany;  the  values  are  based  on  data  from  Tab.B.1  and  on  information  given  by  the 
German  Radiation  Protection  Board  (SSK)  (  4).  The  essential  conclusion  is,  although  very 
tentative,  that  for  a  subpopulation  of 60000  infants  born  in  1987  (roughly  those  prenatally 
exposed)  in  the  southeast  of Bavaria  there  might  be  an  increase  of 9  cases  of childhood 
cancer  in  the  next  10  years  (com pared  to  60  cases  expected,  background  rate).  This  would 
correspond  to  an  excess  relative  risk  of about  15%  which  could  be  at  the  lower  limit  of 
detectability  (Sect.4.2).  If most of the excess  cases  appeared within  the next  5years  (say  about 
5  or  6  cases)  a  reduced  observation  time  could  be  sufficient.  The  background  risk  for 
childhood  cancer  between  age  0  and  5  years  is  about  5-l 0-4,  corresponding  to  30  expected 
cases.  This would  result in  an excess  relative risk  of about 15  to 20%. 
- 66  -il 
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Fig.B.1 
·*· 
6.10  . 
(Kiev) 
:~. 
18  • 
(Kiev) 
Measured  cumulated  I-131  (a)  and  Cs-137  (b)  activitiy  de-
positions per unit area  (the unit is kBq/m2 )  (3). 
- 68  -Adult ext. 
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f.  - - ~t!_! 
~h.!.d~  t~la.!_ 
crlt.  total 
Fig.B.2  Average  doses  (in  mGy)  in the first year due  to  the 
accident.  External,  internal and  total doses  are given 
for adults.  In addition,  the averages  of  the total doses 
are given  for  children and  for  socalled critical groups. 
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 Entire  Infants 
population 
thyroid  thyroid 
dose  I  mGy  dose  I  mGy 
Belgium  0.2  2  - 10 
Denmark  0.1 
France  0.2  1  - 10 
FR  Gennany  0.5  - 1.0  5  - 10 
South  1.0  - 3.0  10  - 30 
Greece  1.0  - 2.0  10  - 20 
Ireland  0.3  10 
Italy  1.0  - 2.0  4.0 
North  "1.0  - 2.0  5.0 
Luxembourg  0.3  2  - 10 
Netherlands  0.4  1  - 5 
Portugal  0.0  0.1 
Spain  o.o  0.1 
United  Kingdom  0.2  1  - 10 
Tab.B.2  Estimated thyroid doses  for  the entire population 
and  for  infants  in the first year after the Chernobyl 
accident. 
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 Annex C: 
Registries of Congenital Malformations and Tumours 
Congenital malformations 
Registries  of congenital malformations and of chromosomal disorders have been set up  in  most 
EC  countries.  Two  coordinating  bodies  for  these  registries , have  been  operating:  the 
International  Clearing House  for  Birth  Defects  Monitoring  Systems  (lnt.Cl.)  and  Eurocat.  The 
lnt.Cl.  was  founded  in  1974  and  currently  it  coordinates  data  from  24  monitoring  systems  all 
over  the  world.  Within  the  EC,  a  Concerted  Action  on  Birth  Defects  was  initiated  in  1979 
with  the  creation  of  Eurocat.  During  the  first  5  years,  registries  were  created  and  the 
standardization of data collection was  tested. 
These  two  coordinating  systems  function  differently:  Eurocat centralises  all  the  data  from  the 
registries  and  carries  out  the  analyses;  the  lnt.Cl.,  in  view  of its  world  coverage,  relies  on 
registry leaders to provide the necessary information and to perform validation checks. 
Tab.C.1  lists  EC registries  on  birth  defects  and  chromosomal  anomalies  together  with  their 
affiliation  and  some  general  characteristics  (1,  2).  Registries  operate  in  eight  of the  12  EC 
countries,  monitoring  in  total  about  1.5  million  births.  The  time  lag  of surveillance  varies 
between  registries  from  1 week  up  to  1 year.  National  centralized  registries  exist  in  only  two 
countries,  Denmark and  Great Britain.  Note that there  are currently  no  operative registries  in 
Greece  or Southern  Germany,  and  that  the  registry  of Emilia  Romagna  covers  only  a  minor 
part  of Northern  Italy.  On  the  other  hand,  these  3  regions  have  had  the  highest  level  of 
caesium  deposits. 
Tab.C.2  lists  the congenital  anomalies  recorded  by  Eurocat  together with  their prevalence  (3); 
those  which  appear  also  in  the  classification  by  lnt.Cl.  are  underlined.  The  anomalies  which 
- 73  -are detailed  per class  are those  for  which  defining  criteria  are most  rigorous  and  least  subject 
to misdiagnosis. 
During  the  past  decade,  prenatal  diagnosis  of chromosome  aberrations  by  amniocentesis  has 
been  practised  to  a  different  extent  in  European  countries.  An  analysis  of the  reports  from 
amniocentesis  (or  chorium  biopsy)  centres  can  provide  information  on  incidences,  specific  to 
maternal age of chromosome aberrations. 
A  combined  analysis  of 52  965  prenatal diagnoses  (performed  because  of age  criteria)  in  59 
amniocentesis  centers  (51  of which  were  in  EC  countries)  has  been  carried  out  on  data 
collected  up  to  and  including  1987  (4).  This  analysis  provides  a  base  line  for  chromosomal 
anomalies  before  Chemobyl.  To  our  knowledge,  no  further  analysis  of such  data  has  been 
planned. The geographic spread of amniocentesis centres in  Europe would  make such  analyses 
potentially  interesting  in  the  context  of the  Chernobyl  accident.  In  France,  there  is  national 
centralization  of prenatal  diagnostic  data,  but  there  is  no  similar  centralization  in  the  other 
countries of the EC. 
Most  of the registries  were  started before  1980  and  they  can,  consequently,  provide estimates 
of pre-Chernobyl  baseline  prevalences  of particular  congenital  anomalies,  calculated  over  at 
least 5 years.  The fraction  of total births  monitored  by  the registries  in  each particular area  is 
high  (over  90% ),  and  hence  the  possibility  of  a  bias  through  increased  reporting  after 
Chemobyl  is  small.  But  possible  bias  must,  nevertheless,  be  borne  in  mind.  The  registries 
which  indicate  100%  coverage  carry  out  periodic  checks  of their  completeness  on  particular 
anomalies. 
It will  be  important  to  select  those  anomalies  for  which  the  defining  criteria  are  clearest. 
Indeed  many  anomalies  show  a  decreasing  trend  when  considered  overall,  but  they  exhibit 
fairly  stable  trends  when  specific  subsets  of  anomalies  are  considered  (3).  This  is  the 
consequence  of  decreasing  levels  of  reporting  for  minor  anomalies.  Particular  subsets  are 
outlined  in  Tab.C.2.  In  general,  there  are  considerable  geographical  variations  of rates  (an 
- 74  -extreme  case  being  that  of  spina  bifida ).  These  variations  are  certain  to  outweigh  any 
geographical  variation  induced  by  radiation.  The  rate  of chromosomal  anomalies,  however,  is 
fairly  stable;  it  is  lowest  in  Odense  (10.8/1()4  births)  and  highest  in  Galway  (33.9 I 104  births). 
The maternal age structure needs  to  be taken into account  as  a highly  important factor  in  any 
analysis of data. 
Tumours 
Tab.  C.3  gives  an overall synopsis  of existing  registration procedures  in  the EC;  it  is  based on 
publications of the International Agency  for  Research on Cancer (IARC) of the World  Health 
Organisation  (WHO)  CCancer  Incidence  in  Five  Continents'  (Vol.  V,  in  preparation)  and  a 
specialised volume on Children's Incidence (in  press)). 
The listed  registries  are population  based,  i.e.  they  aim  to  retrieve  all  cancer cases  of persons 
residing  in  a specified  area.  To  achieve  this,  they rely  both on voluntary  information  provided 
by  hospitals  and  doctors  and  on an  active  search  through  visits  and  telephone  contact.  They 
have permanent staff. 
Children's  cancer  being  of primary  importance,  we  list  in  Tab.C.4  some  of the characteristics 
of the registries which could be used  for  a study of trends in  childhood cancers. 
To  summarise  these  tables,  one  can  state  that  national  coverage  of  childhood  cancers  is 
achieved  by  4  countries  (Denmark,  Fed.Rep  of Germany,  Great  Britain  and  Spain),  in  the 
Netherlands  only  leukaemias  are  covered.  Three  countries  have  only  regional  registries.  The 
percentage  of histologically  confirmed  cases  is  around  90%  for  most  registries  and  nearly  all 
carry  out checks  on duplicates,  coding  errors  and  completeness.  The latter  is  estimated  to  be 
about 90%.  Hence,  there are fairly  similar standards of registration. 
Among  the  regions  with  the  highest  degree  of contamination  after  the  reactor  accident  and 
with  the  highest  individual  doses  there  exists  only  in  the  Fed.Rep  of Germany  a  sufficiently 
- 75  -comprehensive  registry  with  more  than  1 000  cases  (age  0 to  14)  collected  per year  (national 
birth  rate:  600  000  per  year;  childhood  cancer  rate:  13/100  000  per  year).  In  Italy  the 
registration of childhood cancer is  poor, in  Greece there is  no  registry at all. 
Studies undertaken in the EC 
A  study  of teratogenic  defects  in  the  period  after  the  Chernobyl  accident  was  conducted  by 
Eurocat,  and  it  is  to  be  published  shortly  (5).  The  results  of this  study  do  not  show  any 
systematic increase in  the frequency of malformations in  nine countries of Western Europe. 
A  preliminary study  of chromosomal  anomaly  rates  before and  after Chernobyl  has  also  been 
conducted  by  Eurocat.  It,  too,  has  not  indicated  an  increase.  This  preliminary  study 
concentrated  mainly  on  Down's  syndrome.  A  re-evaluation  over  a  longer  period  is  currently 
planned. 
At the 1987  annual  meeting of lnt.Cl.  it  was  agreed  to  follow  the consequences  of Chernobyl 
in  two  ways:  by  an  analysis  of certain selected  malformations  and  by  an  analysis  of the birth 
prevalence  of the  routinely  reported  malformations.  The  results  of these  analyses  should  be 
made public in the near future. 
A working  group  comprising  most  European tumour registries  was  constituted  at the initiative 
of  the  I.A.R.C  (International  Agency  of  Research  on  Cancer).  Registries  have  agreed  to 
coordinate the monitoring of leukaemia trends  for  the next  10 years,  and  to  provide incidence 
data  from  1980  to  April  1986  in  order  to  compute  baseline  incidences.  The  data  will  be 
broken  down  by  sex,  age,  and  region  for  a  total  population  of about  1-2  million.  Exposure 
data for subregions considered in  this study will  be provided by  OECD and  others. 
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- 77  -Table  C.1  EEC  registries on  birth defects and  chromosomal  abnormalities* 
Country  Registries  Affiliation  No.  of  births  Starting date  % of  total 
monitored  ( 1)  of  registry (2)  births 
(average/year)  monitored  <3> 
Belgium  West  Flanders  Eurocat  7 500  1956  96% 
Hainaut  Eurocat  8 000  1979  90% 
Denmark  Odense  Eurocat  4 500  1979  95% 
National  Int.  Cl.  54  000  1978  100% 
France  Paris  both  40  000  1976  ~100% 
Strasbourg  both  13  500  1979  >  90% 
Rhone-Alpes  Auvergne  Int.  Cl.  85  000  1973  ~100% 
Marseilles  Eurocat  23  000  1982  100% 
Germany  West  Berlin  Eurocat  18  000  1980  97% 
Great  Britain (4)  England  &  Wales  Int.  Cl.  660  000  1972  100% 
Glasgow  Eurocat  13  000  1972  ~100% 
Liverpool  Eurocat  20  000  1960  96% 
Northern  Ireland  both  27  900  1971  -Q 100% 
(Belfast) 
Greece  (5) 
Ireland  Dublin  Eurocat  25  000  1979  ~100% 
Galway  Eurocat  NA  1981  ~100% 
Italy (6)  Firenze  Eurocat  8 900  1979  98% 
Umbria  (7)  Eurocat  7 000  1980  91% 
Emi l i a  Romagna  both  21  800  1978  90% 
Multicentric Reg.  Int.  Cl.  131  400  1978  NA 
(147  hospitals)(8) 
Luxembourg  Eurocat  2 200  1980  ~ 50% 
Netherlands  Groningen  Eurocat  7  700  1981  :::100% 
Spain  32  hospitals  Int.  Cl.  67  600  1978  NA 
nationwide 
NA:  not  available 
(1)  For  Eurocat  registries,  the number  of  births monitored  was  evaluated  in 1983. 
For  Int.  Cl.  the number  of  births monitored  was  evaluated  in 1985. 
<2>  For  registries set up  before  the beginning  of  Eurocat  in  1979,  the early data does  not  often conform  to Eurocat  methods 
For  Int.  Cl.  registries,  when  the starting date was  not  available,  the earliest year  on  which  a  base  line is calculated 
is indicated. 
(3)  This  percentage  is evaluated by  each  registry by  comparing  the number  of births taking place  in the monitored maternity 
units and  the number  of  birth certificates in the given area.  A registry which  claims  almost  complete  coverage 
is  indicated as  ~100%.  National  registries are indicated as  100% 
(4)  A Eurocat  registry in South  Glamorgan  was  started in 1985. 
(5)  A registry of  congenital  anomalies  in Evia  was  in operation from  1980  to 1983  and  could provide a  baseline estimation 
of  pre-Chernobyl  rates for this area. 
(6)  A Eurocat  registry in North-East  Italy was  started in 1985. 
<7>  The  registry in Umbria  is part of  the Multicentric Registration. 
(8)  This  co-ordination started with  28  hospitals  in 1978. 
*  This  table was  compiled  from  two  sources: 
-Registration of  congenital  anomalies  in Eurocat  centres 1979-1983  edited by  P.  De  Wals,  J.A.C.  Weatherall  and 
M.F.  Lechat  (1985) 
- International  Clearing  House  for Birth Defects  Monitoring  Systems,  annual  report  1985. 
- 78  -Table  C.2  Prevalence of  congenital  abnormalities  in 17  Eurocat  registries 
(per  10  000  births)  (1980-1983) 
Anomalies  of  the nervous  system 
Congenital  anomalies  of  the eye 
Congenital  anomalies  of  the ear 
Cardiovascular  anomalies 
(including congenital  heart disease) 
(including a  rate of  21.0 of  diagnosis 
not  specified) 
Facial  cleft anomalies 
Digestive system  anomalies 
Anomalies  of  external  genital  organs 
Anomalies  of  internal  urogenital 
system 
Anomalies  of  limb 
Other  anomalies  of  musculoskeletal 
and  corrective tissues 
Chromosomal  anomalies 
31.4 
5.8 
8.1 
52.1 
50.1 
15.1 
19.0 
17.6 
7.4 
59.1 
32.2 
18.6 
[
dysraph;c 
hydrocephalus 
_microcephalus 
r
anophthalmos 
microphtalmos 
cataract 
[
anotia-microtia 
absence  or 
stricture of  the 
auditory canal 
hypoplastic  left 
[
anencephaly 
21.3  spinabifida 
encephalocele 
iniencephaly 
5.1 
3.3 
0.4 
1.2 
1.1 
0.5 
0.8 
heart  1.8 
univentricular 
heart  1.3 
common  truncus  0.9 
non  corrected 
transposition of 
_the  great arteries  2.9 
1
-cleft palate 
cleft  lip 
_both 
[
tracheo-oesophageal  fistula 
oesophageal  atresia and  stenosis 
atresia and  stenosis of  rectum 
and  anal  canal 
atresia and  stenosis of 
small  intestine 
[
hypospadias 
indeterminate sex 
[
renal  agenesis 
cystic kidney 
[
polydactyly 
syndactyly 
limb  reduction 
congenital  deformities of feet 
[
anomalies  of  diaphragm 
anomalies  of  abdominal  wall 
including:  omphalocele 
gastroschisis 
Down  svndrome 
trisomy  18 
trisomy  13 
deletion 
balanced autosomal  translocations 
gonadal  dysgenesis  (Turner's syndrome) 
Klinefelter's syndrome 
other autosomal  anomalies  and  trisomies 
other sex  chromosome  anomalies 
Anomalies  underlined  reported by  the  International  Clearing  House  in its 1985  report. 
0.2 
10.9 
1.8 
0.4 
6.3 
3.1 
5.6 
3.0 
3.6 
1.9 
10.5 
1 
3.4 
2.0 
7.9 
6.2 
5.9 
24.9 
2.7 
6.1 
2.2 
0.5 
13.2 
2 
0.8 
0.4 
0.01 
0.9 
0.2 
1.0 
0.3 
*adapted from:  Surveillance of  congenital  anomalies  years  1980-1983  Eurocat  report  1,  edited by  P.  De  Wals  and 
M.F.  Lechat  (1986). 
- 79  -Table  C.3  Population-based  registries in  EEC  countries  in operation before 1980 
Country  General  registries  National/Regional  Child  registries  National/Regional 
Call  ages) 
Belgium  No  (1)  No 
Dervnark  Yes  N (2) 
France  Yes  R (3)  [Yes]  (4)  R 
Germany  Yes  R (5)  Yes  N (6) 
Great  Britain  Yes  N (7)  Yes  N/R  (8) 
Greece  No  (9)  No 
Ireland  Yes  R (10)  [Yes]  (11)  R 
Italy  Yes  R (12)  Yes  R ( 13) 
Luxembourg  No  No 
Netherlands  Yes  R ( 14)  Yes  (15)  N 
Portugal  No  (16>  No 
Spain  Yes  R (17)  [Yes]  ( 18)  N 
Entries  in  [  ]  do  not  strictly meet  the chosen  requirements 
(1)  There  is a  national  registration of  cancer cases notified by  health  insurance companies  since 1969  and 
reorganised  in 1983. 
(2)  The  Danish  cancer  registry started in 1942  and  covers  both  adult and' childhood tumours. 
(3)  Calvados,  Doubs,  Isere and  Bas-Rhin  established between  1974  and  1978. 
(4)  The  2 childhood tumour  registries started after 1980:  Lorraine  (1983),  Provence-Cote d'Azur-Corse  (1984). 
(5)  Saarland established in 1966. 
(6)  Co-operative Registry started in 1980. 
(7)  Cancer  registration in England,  Wales  and  Scotland  is carried out  by  population-based  regional  cancer  registries with 
national  coverage  since 1962. 
(8)  There  is a  national  registry of  Childhood  Tumours  for Scotland,  England  and  Wales  as well  as  a  registry in Manchester 
and  in the West  Midlands. 
(9)  The  Greek  Ministry of Social  Services collects cases of cancer  reported by  hospitals and  x-ray  laboratories. 
(10)  Southern  Ireland Tumour  Registry has  been  operating since 1977. 
(11)  A childhood  cancer  registry started in Dublin  in 1983. 
(12)  Lombardy  (Varese),  Parma,  Ragusa  (only since 1981). 
(13)  Province of Torino. 
(14)  Eindhoven  registry started  in 1955. 
(15)  Leukemia  only. 
(16)  Only  hospital  based  registries. 
(17)  Navarra,  Zaragosa,  Catalonia  (Tarragona)  since 1980. 
(18)  The  national  registry covers  over  thirty collaborating centres but  is not  population based. 
- 80  -Table  C.4  Characteristics of  registries which  could be  used  for a  study 
of  trends  in childhood cancers  in the EEC 
(1)  (2)  (3)  (4)  (5)  (6) 
Registry  Annual  av.  pop.  First data  % Histol.  Dupl.  Exhaus.  % Exh.  Coding  Possibility 
m +  f  (0-14)  (year)  check  check  errors  of  more  inf. 
(thousands)  check 
Danish  Cancer  1076  1943  93.5%  Yes  Yes  96%  Yes  Yes 
Registry 
Childhood  Cancer  535  1983  93%  Yes  Yes  90%  No  Yes 
Registry of 
Lorraine 
Childhood  Cancer  809  1984  97.5%  Yes  Yes  95%  Yes  Yes 
Registry of  PAAC 
Cancer  Registry  200  1975  94%  NA  NA  NA  NA  NA 
of  Bas-Rhin 
Cooperative  Registry  9962  1980  70%  No  Yes  90%  Yes  Yes 
of  Childhood  Malig-
nancies  in  FRG 
Cancer  Registry  237  1967  85.1%  Yes  Yes  90%  Yes  Yes 
of  Saarland 
National  Registry  1257  1959  NA  Yes  Yes  90%  Yes  Yes 
of  Childhood 
Tumours  in Scotland 
National  Registry  11116  1962  90%  Yes  Yes  90%  Yes  Yes 
of  Childhood  Tumours 
England  &  Wales 
Manchester  943  1954  96%  No  Yes  98%  Yes  Yes 
Children's Tumour 
Registry 
West  Midlands  1025  1957  99.8%  Yes  Yes  95%  Yes  Yes 
Children's Tumour 
Registry 
Childhood  Cancer  1044  1983  99.8%  Yes  Yes  95%  Yes  Yes 
Registry of  Dublin 
Childhood  Cancer  500  1967  88%  Yes  Yes  95%  Yes  Yes 
Registry of  the 
Province of  Torino 
South  East  Registry  192  1955  98%  Yes  Yes  95%  Yes  Yes 
Eindhoven 
Dutch  Chi ldhood  3336  1973  100%  NA  Yes  97%  NA  Yes 
Leukemia  Group  Study 
National  Childhood  not  population  1980  NA  Yes  Yes  NA  Yes  Yes 
Cancer  Registry  based 
of  Spain 
Cancer  Registry  186  1960  75.7%  Yes  Yes  90%  Yes  Yes 
of  Zaragosa 
(1)  Percentage of  recorded cancer  cases confirmed  by  microscopic  examination. 
(2)  Specific procedure  for checking  duplicate recordings. 
(3)  Specific procedure  for checking  exhaustivity of  recordings. 
(4)  Approximative  estimation given  by  the registry of  completeness  of  recordings. 
(5)  Checking  of  diagnosis codification errors. 
(6)  Possibility of  getting back  to the  initial hospital  file of  the cancer  case. 
This  table was  compiled  from  two  sources.  IARC  forthcoming  publication in Childhood  Cancer  Incidence on  Five  Continents 
and  an  IARC  report  on  Cancer  Registration  in the  EEC  (1~87).  Apart  from  specialised childhood  registries,  only  general 
registries which  have  been  in operation for  over  10  years are  included. 
- 81  -Annex D 
Statistical Power of Monitoring Studies of Incidence or Mortality Trends 
The power of any epidemiological study depends on its  design.  The most critical steps are the 
choice  of the parameters to be assessed,  the control  of confounding  factors,  the definition  of 
sample sizes  and  the  use  of appropriate statistical  techniques.  We  shall  discuss  each of these 
aspects and relate them to monitoring potential health effects of the Chernobyl accident. 
Choice of the parameters 
The  choice  must  be determined  by  two  principal  considerations:  minimizing  of measurement 
errors  and  maximizing  the  sensitivity  of  the  study.  Hence,  it  will  be  important  to  have  a 
detailed map of the radioactive deposits and  an assessment both of the collective doses  and  of 
the doses  to sensitive  subgroups,  such  as  children  or pregnant women.  Any  study would  need 
to  concentrate  on  these  subgroups  and  to  assess  with  the  best  possible  methods  the  most 
sensitive  effects.  A  study  on  childhood  cancer,  especially  leukaemia,  through  cancer  registries 
appears to be the most  promising approach to identify  any  health effect duP  to the Chernobyl 
accident. 
In these studies comparisons  should  be made between groups  with  high  and  low  exposures.  A 
pooling  of all  the  data  from  European  registries  would  lead  to  a  dilution  of the  potential 
effect and  to a decrease of power. 
Confounding factors 
Confounding factors  need  to  be taken into  account,  both in  the design of any  epidemiological 
study  and  in  the  statistical  analysis  of the  resulting  data.  In  the  analysis  of temporal  and 
regional  variations  in  aggregated  data,  such  as  incidence  rates,  confounding  factors  can  be 
particularly  important,  and  certain  parameters  can  exhibit  strong  correlation  without  a  direct 
- 82  -causal  interrelation  (1 ).  It  is  usually  difficult,  to  determine  the  geographic  variations  in  such 
confounding  factors.  Hence,  it  will  not  be  feasible  to  assess  possible  post-Chernobyl  health 
effects  by  a  mere  comparison  of rates  in  areas  with  different  exposure;  the  expected  effects 
are far smaller than the differences due to unknown genetic or environmental factors. 
On  the  other  hand,  the  influence  of  confounding  factors  is  largely  cancelled  when  one 
compares incidence  rates  before  and  after an event in  the same geographic  region.  It is  then 
sufficent  to  control  confounding  factors  that  vary  on  the  time  scale  of  the  investigation. 
Furthermore, it may be reasonable to  assume overall similarity of time  trends between regions 
with  smaller  and  higher  exposures,  and  this  would  tend  to  remove  the  influence  of  these 
confounding  factors  when  tern poral  changes  of incidence  between  two  regions  are  com pared. 
Such comparisons are, therefore, appropriate for  inclusion in  the study design. 
Sample size and the power of a comparison 
Because  the  minimum  detectable  risk  depends  on  the  sample  size  of any  epidemiological 
study,  this  linkage will  be examined  here,  and  some notions  that are frequenctly  considered  in 
this  context will  be introduced. 
Relative risk and excess relative risk 
Definition of basic quantities: 
Assume  that  a  disease  occurs  with  rate,  r0(t),  in  a  nonexposed  reference  (control)  population 
and with  rate, re(D,t),  in  the exposed  population. The latter is  a function of dose,  D, and  time, 
t.  The cumulative  rates,  R(t),  (i.e.  R0(t)  or Re(D,t)),  are  the  integrals  of r(t) over  the obser-
vation period 0 to t: 
t 
R(t) = f r(t') dt' 
0 
(1) 
- 83  -For a simple example assume  that there are  ~ cases  in  a population of constant size  N in  the 
i-th year of observation. The cumulative rate,  R(k),  up  to the k-th year is  then obtained as  the 
sum  of the~ (i~) divided  by  N. 
The  ratio  of the rates,  re(t)/r0(t),  is  frequently  termed  the  relative  risk,  RR(t).  In the general 
case the relative  risk  depends on the time,  t,  after the exposure or after the beginning of the 
exposure: 
RR(t) =  re(t)/ro(t)  (2) 
The excess  relative risk,  ERR(t), is  a measure of the enhanced rates in  the exposed group: 
re(t)-ro(t)  re(t) 
ERR(t) =  = - - 1 = RR(t) - 1  (3) 
ro(t)  r0(t) 
The  relative  risk  model  (see  Sect.3.2.1.1)  postulates  a  rate,  re(t),  that  is  proportional  to  the 
spontaneous  age  dependent  rate,  r0(t).  This  implies  that  - after  an  initial  latent  period  - the 
relative risk,  RR,  is  constant in  time. It will,  however,  depend on dose D,  sex S,  and  age A at 
exposure: 
re(t)  = RR(D,S,A)· r0(t)  (4) 
Thus,  in  the relative  risk  model,  the relative  risk,  RR,  and  the excess  relative  risk,  ERR,  do 
not depend on time during a follow-up  study. 
The  subsequent  considerations  are  more  general,  and  include  the  case  of  time-dependent 
factors.  In particular they include also  the absolute risk  model  (see Sect.3.2.1.1)  that is  relevant 
to leukaemias and childhood  tumours. 
- 84  -Power of statistical tests 
The  attainable  power  of a  one-sided  test  of the  alternative  ERR=O  (no  excess  risk  in  the 
exposed  group  in  comparison  to  the unexposed  control group) versus  ERR>O (excess  relative 
risk)  can be expressed  in  terms  of the expected  number,  no,  of cases  in the control group  and 
the  magnitude  of  ERR  in  the  exposed  group  which  is,  for  the  purpose  of  subsequent 
examples, assumed to be equal in size to the non-exposed  population. 
Using  the normal  approximation  to  the Poisson  distribution  (a  good  approximation  for  nc>lO, 
otherwise see (2))  one finds  the power,  which  is  defined  as  the probability of obtaining a  test 
result that is  significant at a chosen level, a: 
with: 
ZB  =  ~  ·  ERR 
~(z) is the  standard-normal distribution: 
t(z)  = 
1 
J2n
1 
z 
J 
-oo 
2  -x  /2  e  dx 
(5) 
To illustrate  the use  of Eq(5) one can derive,  with  the assumed  data from  Tab.B.3,  estimates 
of the probability of detecting an increase  in  childhood  cancer, when  a  specified  population is 
observed for  a  period,  t,  before the exposure and,  subsequently,  for  the same period after the 
exposure. 
The following  symbols  are employed: 
- 85  -no  number of expected cases in  the nonexposed group: 
No  number of individuals  in  each group 
t  duration of observation 
ro  background rate of cases 
ERR :  excess  relative risk 
a  significance level of the test 
Za  normal upper one-tailed deviate to the level  (z)=1-a 
cp(z/3  -za ) :  probability that the test result will  be significant at the level a 
With the assumptions in Tab.B.3 one obtains for infants in  southern Bavaria: 
ERR=0.15; t=10a;  No=60 000;  r=10-4/a;  no=  60 
From  Eq(5) one has:  z3=0.8 
and with  z5%  =  0.13  one has:  cp(0.67)=0.25. 
For  the  one-tailed  5%-significance  level  there  is  a  probability  0.25  of detecting  the  assumed 
increase. 
For  general  guidance  one  can  use  - instead  of Eq(5)  or  its  more  complicated  analogue  for 
unequal  group  sizes  - a  simple  comparison  of the  expected  number  of excess  cases  with  the 
Poisson  variance  of  the  difference  of  observed  cases  in  the  two  groups  under  the 
null-hypothesis.  Thus,  one has  in  the  example  of the  infants  in  southern  Bavaria  the variance 
no+no=120  of the  difference  under  the  null-hypothesis,  i.e.  a  standard  deviation  of/120~11. 
Under the assumed  excess  relative  risk,  ERR=0.15,  the expected  number of excess  cases  is  9. 
Since  this  lies  somewhat below  the standard  deviation  ( < 11)  one expects  a  poor to  moderate 
chance  of  finding  a  'significant'  difference.  If the  number  of  expected  excess  cases  were 
between  one  standard  deviation  and  twice  the  standard  deviation,  one  would  expect  a 
- 86  -moderate chance of seeing the increase. If it were to exceed  twice  the standard deviation,  one 
would  expect a good chance. 
These  simplified  considerations  are  readily  extended  to  the  case  of different  population  sizes. 
Let  No  and  Ne  be  the  population  sizes  and  r=Ne!No  the  ratio  of the  sizes.  The  observed 
number of cases,  ne,  in  the exposed  group  minus  the  product of r  and  the observed  number, 
ll0 ,  in  the  control  group  can  then  be  termed  the  number,  ne"'  of excess  cases.  Under  the 
nullhypothesis,  nex  has  - as  is  readily  derived  - the  standard  deviation a =/ne(l +r).  The 
expected  number of excess  cases,  ne. ERR, for  the assumed  ERR must exceed  2 a for  a  'good 
chance'  of  a  significant  observation.  Using  as  index  the  ratio,  ne 4 ERR/(2a),  one  obtains, 
therefore, the useful necessary condition for  a study: 
ERR~e 
-- -->1  2  1+r 
(6) 
where  ERR  is  the  excess  relative  risk,  ne  is  the  expected  number  of cases  in  the  exposed 
group  under  the  null-hypothesis  (ERR=O),  and  r  is  the  ratio  of sizes  of the  exposed  and 
control populations. 
For  the  above  example  one  obtains  a  ratio  of 0.41.  Thus  one  concludes  that  the  success 
probability is  poor. This  is  in  line with  the more quantitative power calculations from  Eq(5). 
It must be noted that the condition of a Poisson distribution of cases need not always  apply. If 
interdependent cases  occur,  Poissonian  tests  will  be invalid;  the  clustered  occurrence  of cases 
of  Down's  syndrome,  due  to  possibly  unrecognized  viral  infections,  are  an  example.  This 
complication must be kept in  mind with  regard to the above considerations. 
There are additional reasons  for  failure  of the computations of statistical  power  to correspond 
to the reality of an epidemiological study.  As  stated, they disregard confounding factors  that 
- 87  -may  be different in  two  populations or may  change in  time  in  a  population.  The presence of 
confounding factors  is  usually  the major limitation of an epidemiological study,  and the formal 
consideration  of the  statistics  of case  numbers  must  not  distract  from  this  far  more  difficult 
aspect. 
There  may  be various  approaches  reducing  the  influence  of confounding  factors,  but  these 
approaches  may  often  be  mutually  exclusive.  As  stated  at  the  beginning  of this  section,  one 
can,  by  comparing  contemporaneous  populations,  largely  reduce  the  influence  of confounding 
factors  that  are  due to secular  changes;  however  one incurs,  thereby,  the  usually  unavoidable 
disadvantage that the two  populations may' differ in  other important aspects. 
If,  on the other hand, secular trends are of minor concern or if they can be corrected in  terms 
of known  population rates,  it  may  be more advantageous to compare observations in  the same 
population before and  after the event of interest.  This  is  reflected  in  the choice  of the above 
examples for  power computations. 
Statistical methods 
Time  series  methods  are  designed  to  model  the  trend,  seasonal  variations,  and  the  residual 
fluctuations  of  an  observed  set  of  chronologically  ordered  data  points  (3).  The  trend  is 
estimated  either  by  linear  or  quadratic  variations  or  by  a  moving  average.  The  residual 
fluctuations  are  assumed  to  be stationary  and  modelled  by  an  ARMA (!!utoregressive  moving 
!!Verage)  process. 
Furthermore,  one can incorporate the effect of an 'intervention' into this  modelling procedure, 
and this  makes  it  possible to  test at specified  times  for  shifts  (sudden or gradual) of the mean 
(  4).  The drawback of these methods  is  that they require  a time series of sufficient  length with 
the constraint that the random  errors be normally distributed.  For instance,  the methods might 
be applicable to  the study of childhood  cancer or leukaemia incidence over 20  years  (10  years 
- 88  -before and  10  years  after the reactor  accident)  for  data broken down  by  trimesters  and for  a 
population with  at least 5 expected  cases  per trimester.  For shorter series,  it  might  merely be 
possible to estimate a  trend before the event and  to test whether the observed  rates after the 
event lie within  the confidence interval of the predicted trend (5). 
Other methods,  such  as  the cumulative  sum  technique  (CUSUM) or sequential  analysis,  have 
been proposed in  the context of monitoring of congenital malformation frequencies  (6).  These 
methods  are designed  specifically  to detect quickly  any  increase in  the number of cases,  rather 
than  to  study  time  trends.  A  test  for  detecting  a  'change  point'  in  a  Poisson  process  was 
recently applied to study the rates of hypospadias in Liverpool (7). 
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- 90  -Annex E 
Quantities and Units 
The multiplicity of radiation quantities and  units  has  led to  confusion and  to misinterpretations 
after  the  reactor  accident  and  the ensuing  radioactive  contaminations  in  the  countries  of the 
EC. 
The  use  of  more  than  one,  or  even  a  few  quantities  and  units  is,  however,  unavoidable 
because of the different properties of radionuclides,  such  as  iodine or caesium,  and because of 
the complexity of different pathways of radiation exposure (see Annex B). 
The  complexity  is  largely  reduced,  when  exposures  are  specified  in  terms  of the  radiation 
energy  actually  absorbed  by  the human body.  The concept of absorbed  dose  (or simply  dose) 
permits  this  specification.  It equals  energy  per  unit  mass,  and  it  is  measured  in  joule/kg  for 
which  the special name gray  (symbol:  Gy)  is  used  (1).  The older unit  of absorbed  dose  is  the 
rad  which  equals  10mGy.  Apart from  two  diagrams  giving  the deposited  activities  per surface 
area  in  different  countries,  the  absorbed  dose  is  the  only  reference  quantity  utilized  in  this 
report;  for  brevity the simpler term dose is  used  for  absorbed dose. 
A  dose can  refer  to  the exposure  of one organ  only,  and  it  is  then of less  consequence  than 
the same dose  applied  to  the whole  body.  Organ doses  and  whole-body doses  must,  therefore, 
be distinguished.  The assessment  of the doses  from  fall-out  due  to  nuclear-weapons  tests  was 
complex because of the multitude of different radionuclides  that had  to  be taken into  account. 
After the reactor accident it was,  at least in  the countries of the EC,  sufficient to consider the 
thyroid  dose  due to  iodine  and  the whole-body  dose due  to  caesium.  The dose values  quoted 
in  this  report refer,  therefore,  either to  the thyroid  or to  the entire body  (including  the bone 
marrow which  is  relevant for  leukaemia-risk estimates). 
- 91  -The concept of effective dose 
In radiation  protection one uses  somewhat  more general concepts, which  are not employed  in 
this  report,  but are nevertheless  of sufficient  interest  to  be considered  briefly.  To  establish  a 
scale  of comparison  between  the  exposure  of a  single  organ  and  the  exposure  of the whole 
body,  the organ  dose  equivalents  are multiplied  by  weighting  factors  which  were  specified  by 
the International  Commission  on Radiological  Protection  (ICRP)  (2).  These weighting  factors 
represent the relative  contribution of the specified  organ  to  the total  risk  from  a  whole body 
exposure (Tab.E.1). The sum  of all  weighting factors  equals unity,  and the sum  of all  weighted 
organ  dose  equivalents  is  called  the  effective  dose.  For example,  a  thyroid  dose  of 5mGy  is 
multiplied  by  the  weighting  factor  0.03  to  result  - when  no  other organ  is  exposed  - in  an 
effective dose of 0.15  mGy.  This  reflects  the judgement that a  dose  to  the whole body carries 
a mortality risk about 30 times  higher than the same dose applied only to the thyroid. 
To  give  the general  magnitude  of doses  resulting  from  the contamination  in  the countries  of 
the European Community after the reactor accident,  one can state that the average increment 
of absorbed dose in  the first  year after the accident in  all  these countries  may have been 0.05 
mGy  due  to  the  external  whole-body  exposure,  0.15  mGy  due  to  the  whole-body  exposure 
from  incorporated  caesium,  and  0.6  mGy  thyroid  dose  due  to  the  incorporated  iodine.  To 
obtain  the effective  dose,  one assigns  to  the whole-body  doses  the weighting  factor  w=  1  and 
to  the  thyroid  dose the weighting  factor w=0.03.  This  results  in  the contribution of 0.05  m  Gy, 
0.15mGy,  and 0.02  mGy,  and,  therefore, in  an effective dose of 0.22  mGy. 
A  further  generalization of the concept of dose  is  used  in  radiation  protection to  account  for 
the different  biological  effectiveness  of sparsely  ionizing  radiations,  such  as  gamma  rays,  or x-
rays,  and of density ionizing radiation, such  as  a -rays  or neutron. The different effectiveness  is 
represented  by  a  qualtity  factor  0, which  has  been  set  equal  to  unity  for  sparsely  ionizing 
radiation  and  equal,  for  example,  to  20  for  a -rays.  Multiplying  the  absorbed  dose  by  the 
qualtity factor one obtains the dose equivalent, which  is  measured in  sievert  (symbol:  Sv). 
- 92  -The  radioactive  contamination  in  Western  Europe  after  the  reactor  accident  contained  - in 
contrast  to  the  nuclear  weapons  fall-out  - no  substantial  amount  of  a -emitters,  such  as 
plutonium.  The  problem  of the  greater  effectiveness  of the  densely  ionizing  a -particles  was, 
therefore,  not  relevant  to  this  report.  For  the  same  reason  there  was  no  need  to  use  the 
concept of dose  equivalent.  Instead  it  was  sufficient  to  use  the absorbed  dose  and  to  express 
even  the  effective  dose  in  Gy,  although  this  does  not  agree  with  the  normal  convention  to 
treat effective dose as  a dose equivalent. 
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